Phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof, preparation method and use thereof

ABSTRACT

A phenanthroindolizidine and phenanthroquinolizidine alkaloid having a hydroxyl group on the phenanthrene ring thereof was synthesized, which exhibits potent activity as an anticancer agent against, such as breast cancer, lung cancer, and prostate cancer.

FIELD OF THE INVENTION

The present invention is related to phenanthroindolizidine andphenanthroquinolizidine alkaloid having a hydroxyl group on thephenanthrene ring thereof, preparation method thereof and use thereof asan anticancer agent.

BACKGROUND OF THE INVENTION

US2010/0216773 A1 discloses a method for preparing aphenanthroindolizidine and phenanthroquinolizidine alkaloid, and inExample 1 thereof a mixture of compounds of 13-16 are allegedlysynthesized by partial hydrolysis of compound 28, where the structuresof the compounds 13-16 and 28 are shown as follows:

These four compounds 13-16 disclosed in US2010/0216773 A1 cannot beobtained by the treatment of compound 28 with sodiumbis(2-methoxyethoxy)aluminium hydride, a reducing agent, according toour previous method. [T. Chuang, S. I Lee, C. W. Yang, P. L Wu Org.Biomol. Chem. 2006, 4, 860-867.].

SUMMARY OF THE INVENTION

The present invention discloses a novel method for preparing aphenanthroindolizidine and phenanthroquinolizidine alkaloid, and inparticular a method for preparing a phenanthroindolizidine aridphenanthroquinolizidine alkaloid having a hydroxyl group on thephenanthrene ring thereof, which shows an improved solubility in anaqueous solvent system and potent cytotoxicity activity against breastcancer, lung cancer, and prostate cancer.

Preferred embodiments of the present invention include (but not limitedto) the following items:

-   1. An improved method for preparing a phenanthroindolizidine and    phenanthroquinolizidine alkaloid having a structure represented by    the following formula (I):

wherein n is 1, 2, or 3; each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, independently, is H, halogen, alkyl,aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, or amino;

-   wherein the improvement comprises the method comprising step (5):    conducting a reductive decyanization reaction of an    aminoacrylonitrile derivative having a structure represented by the    following formula (III) to obtain a diphenyltetrahydropyridine    derivative having a structure represented by the following formula    (II);

-   2. The method of Item 1 further comprising a step (6): conducting an    aryl-aryl oxidative coupling reaction of the    diphenyltetrahydropyridine derivative (II) to obtain the    phenanthroindolizidine and phenanthroquinolizidine alkaloid (I).-   3. The method of Item 1 further comprising a step (4): conducting an    intramolecular aza-DielsAlder reaction of an iminonitrile derivative    having a structure represented by the following formula (IV) and to    obtain the aminoacrylonitrile derivative (III):

wherein definitions of n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹,R¹², R¹³, R¹⁴, and R¹⁵ are the same as in claim 1.

-   4. The method of Item 3 further comprising step (3): reacting a    vinyl amine derivative having a structure represented by the    following formula (V) with an (E)-2,3-diphenylacrylaldehyde    derivative having a structure represented by the following    formula (VI) to obtain the iminonitrile derivative (IV):

HR⁹C═C—CR¹⁰R¹¹—(CR¹⁴R¹⁵)_(n)—CR¹²R¹³NH₂   (V)

wherein definitions of n, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹,R¹², R¹³, R¹⁴, and R¹⁵ are the same as in claim 1.

-   5. The method of Item 4 further comprising a step (2): conducting a    diisobutylaluminum hydride reduction of a diphenylacrylonitrile    derivative having a structure represented by the following    formula (VII) to obtain the (E)-2,3-diphenylacrylaldehyde derivative    (VI):

wherein definitions of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are the sameas in claim 1.

-   6. The method of Item 5 further comprising a step (1): conducting a    Knoevenagel condensation of a benzaldehyde derivative having a    structure represented by the following formula (VIII) and a    phenylacetonitrile derivative having a structure represented by the    following formula (IX) to obtain the diphenylacrylonitrile    derivative h (VII):

wherein definitions of R¹, R², R⁵, R⁶, R⁷ and R⁸ are the same as inclaim 1.

-   7. A phenanthroindolizidine and phenanthroquinolizidine alkaloid    having a structure represented by the following formula (I),

wherein n is 1, 2, or 3; each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, independently, is H, halogen, alkyl,aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, or amino; wherein atleast one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ is OH; and

-   wherein the alkaloid (I) exists without mixing with another    phenanthroindolizidine and phenanthroquinolizidine alkaloid.-   8. The phenanthroindolizidine and phenanthroquinolizidine alkaloid    of Item 7, which is dissolved in water or an aqueous solution.-   9. The method of Item 1, wherein n=R¹, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³,    R¹⁴, and R¹⁵ are H.-   10. The method of Item 9, wherein each of R², R³, R⁴, R⁵, R⁶, and    R⁷, independently, is H, OH, or alkoxy.-   11. The method of Item 10, wherein at least one of R², R³, R⁴, R⁵,    R⁶, and R⁷ is OH.-   12. The method of Item 11, wherein R², R³, and R⁶ are methoxy; and    R⁷ is OH.-   13. The phenanthroindolizidine and phenanthroquinolizidine alkaloid    of Iters. 7, wherein n=2; R¹, R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and    R¹⁵ are H.-   14. The phenanthroindolizidine and phenanthroquinolizidine alkaloid    of Item 13, wherein each of R², R³, R⁴, R⁵, R⁶, and R⁷,    independently, is H, OH, or alkoxy.-   15. The phenanthroindolizidine and phenanthroquinolizidine alkaloid    of Item 14, wherein R², R³, and R⁶ are methoxy; and R⁷ is OH.-   16. A method for treating a cancer comprising administering to a    subject in need thereof an effective amount of a    phenanthroindolizidine and phenanthroquinolizidine alkaloid having a    structure represented by the following formula (I):

wherein n=2; R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵ are H; R², R³, and R⁶are alkoxy; R¹, R⁴, R⁵, R⁷ and R⁸, independently, are H, OH, or alkoxy;and at least one of R¹, R⁴, R⁵, R⁷ and R⁸ is OH; and

-   wherein the cancer is selected from the group consisting of breast    cancer, lung cancer, and prostate cancer.-   17. The method. of Item 16, wherein R², R³, and. R⁶ are methoxy; R¹,    R⁴, R⁵, and R⁸, independently, are H or methoxy; and R⁷ is OH.-   18. The method of Item 17, wherein the alkaloid has a structure    represented by the following formula.:

BRIEF DESCRIPTION OF THE DRAWING

FIG. 1 shows the results of neurotoxicity of compounds 20 and 5isynthesized in accordance with the method of the present invention,determined by a rotarod test for motor coordination.

DETAILED DESCRIPTION OF THE INVENTION

Tylophorine, a phenanthroindolizidine alkaloid, was first isolated fromTylophora asthmatica (Asclepiadaceae) in 1935 by Rathnagiriswaran andco-worker. (A. N. Rathnagiriswaran, K. Venkatachalarn, Indian J. Med.Res. 1935, 22, 433-441) Phenanthroindolizidines andphenanthroquinolizidines exhibit several interesting biologicalactivities such as anticancer, antiamoebic, antibacterial, andantifungal activities; eight comprehensive reviews have been publishedfrom 1978 to 2015. [a) T. R. Govindachari, N. Viswanathan, Heterocycles1978, 11, 587-δ 13; b) I. R. C. Bick, W. Sinchai, Alkaloids 1981, 19,193-220; c) E. Gellert, J. Nat. Prod. 1982, 45, 50-73; d) Z. Li, Z. Jin,R. Huang, Synthesis 2001, 16, 2365-2378; e) C. G. Zhang, X. D. Tan,Sichuan Shifan Daxue Xuebao, Ziran Kexueban 2005, 28, 366-370; 0 S. R.Cheniler, Curr Bioact. Compd. 2009, 5, 2-19; g) A. C. B. Burtoloso, A.F. Bertonha, I. G Rosset, Curr. Top. Med. Chem. 2014, 14, 191-199; h) deFatima Pereira, M., C. Rocliais, P. Dallemagne, Anticancer Agents Med.Chem. 2015, 15, 1080-1091.] Unfortunately, high doses of (R)-tylophorine(1) caused central nervous system (CNS) side effects in rats, and(R)-tylocrebrine (2) failed in the early clinical trial owing to CNStoxicity. [a) C. Gopalakrishnan, D. Shankaranarayan, L. Kameswaran, S.Natarajan, Indian J. Med Res. 1979, 69, 513-520; b) M. Suffness, J.I)ouros, Anticancer Agents Based on Natural Product Models, Academic,New York, 1981, pp. 465-487] The CNS side effects (e.g., disorientation,ataxia, and decreased motor activity) of compounds 1 and 2 and their lowwater solubility urgently need to be addressed before attemptingclinical trials again. A more polar analog, as proposed by Suffuessmentioned above, will minim/ze or prevent the CNS side effects owing todecreased diffusion through the bloodbrain barrier (BBB). Indeed,hydroxylated. cryptopleurine 3 significantly reduced the BBB penetrationas predicted by PreADMET; unfortunately, no further in vivo result wasreported. [X. Yang, Q. Shi, C. Y. Lai, C. Y. Chen, E. Ohkoshi, S. C.Yang, et al., J. Med. Chem. 2012, 55, 6751-6761.]

Although several previously reported routes were concise [a) T. R.Govindachari, N. Viswariathan, Heterocycles 1978, 11, 587-δ 13; b) I. R.C. Bick, W Sinchai, Alkaloids 1981, 19, 193-220; c) E. Gellert, J. Nat.Prod. 1982, 45, 50-73; d) Z. Li, Z. Jin, R. Huang, Synthesis 2001, 16,2365-2378; e) C. G. Zhang, X. D. Tan, Sichuan Shifan Daxue Xuebao, ZiranKexueban 2005, 28, 366-370; f) S. R. Chemler, Curr Bioact. Compd. 2009,5, 2-19; g) A. C. B. Burtoloso, A. F. Bertonha, I. G. Rosset, Curr. Top.Med. Chem. 2014, 14, 191-199; h) de Fatima Pereira, M., C. Rochais, P.Dallemagne, Anticancer Agents Med. Chem. 2015, 15, 1080-1091.], thesyntheses of phenanthroindolizidines and phenanthroquinolizidinesfocused only on specific positions (C-2, C-3, C-6, and C-7) of thephenanthrene ring owing to the limitations of the synthetic methods. Inthe present invention, we envision that a pentacyclic alkaloid with ahydroxyl group on the phenanthrene ring would improve water solubilityand polarity. Thus, we disclose a novel method for synthesizingphenanthroindolizidine and phenanthroquinolizidine alkaloids with threeto five methoxyl groups on C-1 to C-8 positions of the phenanthrenering, and a potent anticancer analog by converting the methoxy groupinto a hydroxyl group was discovered in the present invention.

Herein, we disclose a concise strategy to construct pyrrolizidine andindolizidine systems by a cyano-group-promoted IADA (Intramolecularaza-Diels-Alder) reaction followed by reductive decyanization (Scheme1). A series of phenanthroindolizidines 4 and phenanthroquinolizidines 5were synthesized from decyanization products 10 and 11 via aryl-aryloxidative coupling reactions. This tandem reaction sequence provides anew synthetic approach to this type of pentacyclic alkaloids.

Scheme 2 shows the synthesis of IADA precursors 14a-i and 15a-i. First,the (E)-2,3-diphenylacrylaldehydes 16a-i were synthesized by theKnoevenagel condensation of benzaldehydes 18v-z with phenylacetonitriles19v-z, followed by DIBAL-H reduction (T. H. Chuang, W. Y. Chang, C. F.Li, Y. C. Wen, C. C. Tsai, J. Org. Chem. 2011, 76, 9678-9686). Next,α-iminonitrile 14i was synthesized in a low yield, probably because ofpoor solubility, by the one-pot reaction of acrylaldehyde 16i,pent-4-enylamine, trirnethylsilyl cyanide (TMSCN), 2-iodoxybenzoic acid(IBX), and tetrabutylammonium bromide (TBAB) in CH₃CN following themethod. of Zhu et al. (P. Fontaine, A. Chiaroni, G Masson, J. Zhu, Org.Lett. 2008, 10, 1509-1512) Nevertheless, a two-step method was developedto synthesize 2-(alkenylimino)-3,4-diphenyl-(3E)-butenenitriles 14a-iand 15a-i in good yields via Schiff base formation (Scheme 2).

Next,3,4-bis(3,4-dimethoxyphenyl)-2-(4-pentenylimino)-(3E)-butenenitrile 14iwas selected as the initial model to investigate the feasibility of theIADA reaction. Conventional heating was selected over microwave heating,because the cycloaddition reaction of compound 14i did not reachcompletion under the microwave conditions. A 0.05 M solution of compound14i in toluene in a sealed tube was heated at 165° C. under the maximumpower 250 W for 3 h using a focused microwave reactor. A solution ofcompound 14i in toluene was refluxed for 72 h, affording cycloadduct 12iin 58% yield. A similar result was obtained by heating the mixture in asealed tube at 130 ° C. for 48 h. To our delight, the cycloaddition ofcompound 14i could be carried out in a sealed tube by heating at 160° C.for overnight, affording trans-12i (64% yield) and cis-12i (7% yield).All the IADA reactions of2-(alkenylimino)-3,4-diphenyl-(3E)-butenenitriles 14a-i and 15a-i wereconducted under the above optimum conditions, and the yields are shownin Table 1. The IADA reactions of compounds 14b-i with a three-atomspacer afforded cycloadducts 12b-i in trans/cis ratios of ca. 10:1 asdetermined from their crude ¹H NMR spectra. Interestingly, when IADAprecursors 15a-i with a four-atom spacer were used, stereospecificcycloadducts trans-13a-i were obtained in high yields. Thus, theefficiency of the IADA reactions and the trans/cis diastereomeric ratiosof the IADA cycloadducts are affected by the spacer length. The IADAreactions of 15a-i proceeded exclusively through a more stable exotransition state, affording the thermodynamically less stabletrans-13a-i as the main products.

TABLE 1 Yields of IADA cycloadducts 12 and trans-13

Yield Yield [%] [%] Entry 14 15 Substituent ^([a]) 12 ^([b]) 13 ^([c]) 114a 15a R¹ = R² = R³ = R⁶ = R⁷ = OCH₃ 60 (12a) 84 (13a) 2 14b 15b R³ =R⁶ = R⁷ = OCH₃ 73 (12b) 90 (13b) 3 14c 15c R² = R⁶ = R⁷ = OCH₃ 78 (12c)91 (13c) 4 14d 15d R² = R³ = R⁴ = R⁶ = R⁷ = OCH₃ 67 (12d) 90 (13d) 5 14e15e R² = R³ = R⁵ = R⁶ = R⁷ = OCH₃ 62 (12e) 86 (13e) 6 14f 15f R² = R³ =R⁷ = OCH₃ 70 (12f) 90 (13f) 7 14g 15g R² = R³ = R⁶ = OCH₃ 70 (12g) 92(13g) 8 14h 15h R² = R³ = R⁶ = R⁷ = R⁸ = OCH₃ 78 (12h) 93 (13h) 9 14i15i R² = R³ = R⁶ = R⁷ = OCH₃ 71 (12i) 92 (13i) 9 14i 15i R² = R³ = R⁶ =R⁷ = OCH₃ 71 (12i) 92 (13i) ^([a]) The substituents not mentioned arehydrogens. ^([b]) The IADA reactions of compounds 14b-i with athree-atom spacer afforded cycloadducts 12b-i in trans/cis ratios of ca.10:1. Trans/cis diastereomeric mixtures 12 were used in the next step.^([c]) Diastereomers trans-13a-i were obtained predominantly.

With a series of 6,7-diphenylindolizine-5-carbonitriles (12a-i) andtrans-2,3 -diphenylquinolizine-4-carbonitriles (trans-13a-i) in hand, anefficient method was developed for the removal of the cyano group fromα-aminoacrylonitriles: A mixture of eyeloadducts 12a-i (and trans-13a-i)and 10 equiv NaBH₄ in 2-propanol in a sealed tube was heated at 100 ° C.for 24 h. The decyanization products, 6,7-diphenylindolizines 10a-i and7,8-diphenylquinolizines 11a-i, were obtained in almost quantitativeyields (Table 2).

TABLE 2 Reductive decyanization of α-aminoacrylonitriles 12 andtrans-13.

En- Yield [%] Yield [%] try 12 13 Substituent ^([a]) 10 11 1^([c]) 12a13a R¹ = R² = R³ = R⁶ = R⁷ = OCH₃ 92 (10a) 95 (11a) 2^([b]) 12b 13b R³ =R⁶ = R⁷ = OCH₃ 100 (10b) 100 (11b) 3^([b]) 12c 13c R² = R⁶ = R⁷ = OCH₃100 (10c) 100 (11c) 4^([b]) 12d 13d R² = R³ = R⁴ = R⁶ = R⁷ = OCH₃ 96(10d) 98 (11d) 5^([b]) 12e 13e R² = R³ = R⁵ = R⁶ = R⁷ = OCH₃ 100 (10e)100 (11e) 6^([b]) 12f 13f R² = R³ = R⁷ = OCH₃ 100 (10f) 100 (11f)7^([b]) 12g 13g R² = R³ = R⁶ = OCH₃ 100 (10g) 100 (11g) 8^([c]) 12h 13hR² = R³ = R⁶ = R⁷ = R⁸ = OCH₃ 94 (10h) 97 (11h) 9^([b]) 12i 13i R² = R³= R⁶ = R⁷ = OCH₃ 100 (10i) 100 (11i) ^([a]) The substituents notmentioned are hydrogens. ^([b]) Reactions were carried out at 100° C.and ^([c]) 120° C.

Finally, an efficient oxidizing agent, vanadium oxytrifluoride (VOF₃),was chosen to examine the oxidative aryl-aryl coupling of6,7-diphenylindolizines 10a-i and 7,8-diphenylquinolizinesPhenanthroindolizidines 4b, 4c, 4f, 4g, and 4i as well asphenanthroquinolizidines 5b, 5c, 5f, 5g, and 5i with three or fourmethoxyl groups could be smoothly synthesized. under Park's conditions(method A, entries 2, 3, 6, 7, and 9 in Table 3). [X. Xu, Y. Liu, C. M.Park, Angew. Chem. Int. Ed.. 2012, 51, 9372-9376.] However, an attemptto prepare phenanthroquinolizidine 5a with five methoxyl groups underthe same conditions resulted in extensive oxidative decomposition. Toour delight, phenanthroindolizidines 4a, 4d, 4e, and 4h as well asphenanthroquinolizidines 5a, 5d, 5e, and 5h with five methoxyl groupscould be obtained in good to moderate yields (entries 1, 4, 5, and 8 inTable 3) with complete regiospecificity under mild conditions (method B:2 equiv VOF₃, −20° C.). The total synthesis of phenanthroindolizidines4a-i and phe-nanthroquinolizidines 5a-i from benzaldehydes withphenylacetonitriles was achieved in six steps in 8.8-42.1% and19.3-63.5% overall yields, respectively. To the best of our knowledge,this is a novel and concise strategy to construct these types ofpentacyclic skeletons.

TABLE 3 Aryl-aryl coupling of cis-stilbenes 10 and 11.

Yield Yield [%] [%] Entry 10 11 Substituent ^([c]) 4 5 1 ^([b]) 10a 11aR¹ = R² = R³ = R⁶ = R⁷ = OCH₃ 70 (4a) 77 (5a) 2 ^([a]) 10b 11b R³ = R⁶ =R⁷ = OCH₃ 82 (4b) 88 (5b) 3 ^([a]) 10c 11c R² = R⁶ = R⁷ = OCH₃ 86 (4e)84 (5c) 4 ^([b]) 10d 11d R² = R³ = R⁴ = R⁶ = R⁷ = OCH₃ 89 (4d) 90 (5d) 5^([b]) 10e 11e R² = R³ = R⁵ = R⁶ = R⁷ = OCH₃ 85 (4e) 88 (5e) 6 ^([a])10f 11f R² = R³ = R⁷ = OCH₃ 85 (4f) 86 (5f) 7 ^([a]) 10g 11g R² = R³ =R⁶ = OCH₃ 86 (4g) 88 (5g) 8 ^([b]) 10h 11h R² = R³ = R⁶ = R⁷ = R⁸ = OCH₃54 (4h) 71 (5h) 9 ^([a]) 10i 11i R² = R³ = R⁶ = R⁷ = OCH₃ 85 (4i) 92(5i) ^([a]) Method A: a 0.04M solution of 10 or 11 (0.2 mmol) inanhydrous CH₂Cl₂ (5 mL) was added to VOF₃ (1.0 mmol) at 0° C. and themixture was stirred for 15 min. TFA (2.8 mmol) was added and the mixturewas stirred at 0° C. for 1 h. ^([b]) Method B: a 0.04M solution of 10 or11 (0.2 mmol) in anhydrous CH₂Cl₂ (5 mL) was added to VOF₃ (0.4 mmol) at−20° C. and the mixture was stirred for 15 mm. TFA (2.8 mmol) was addedand the mixture was stirred at −20° C. for 1 h. ^([c]) The substituentsnot mentioned are hydrogens.

Based on the SAR results, a more polar phenanthroquinolizidine,7-hydroxycryptopleurine (20), was designed and synthesized to decreasethe CNS toxicity and increase the water solubility.7-Hydroxycryptopleurine (20) was obtained from3-benzyloxy-4-methoxybenzaldehyde in 40.7% overall yield by the abovenewly developed method.

EXAMPLES

-   1. Synthesis of (Z)-2,3-diphenylacrylonitriles 17a-i

Typical procedure for the synthesis of (Z)-2,3-diphenylacryl nitrile 17according to the literature. ['E H. Chuang, W. Y. Chang, C. F. Li, Y. C.Wen, C. C. Tsai, J. Org. Chem. 2011, 76, 9678-9686] A fresh 1 M NaOEtsolution (prepared from Na (5.06 g, 22 mmol) in absolute EtOH (22 mL))was added in one portion to a stirred solution of benzaldehydes 18v-z(20 mmol) and phenylacetonitriles 19v-z (20 mmol) in absolute EtOH (100mL) at RT. The mixture was heated at 85° C. under N2 for 1 h. If noprecipitate was formed at RT, the mixture was cooled to −20° C. Theresulting precipitate was filtered and washed with small amounts of coldEtOH, affording (Z)-2,3-diphenylacrylonitrile 17a-i. The completespectral data of these compounds are given below.

(Z)-3-(2,3,4-Trimethoxyphenyl)-2-(3,4-dimethoxyphenypacrylonitrile (17a)

Yield 94%; pale yellow needle, mp 107-108° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.89 (3H, s), 3.93 (9H, s), 3.96 (3H, s),6.79 (1H, d, J=8.8 Hz), 6.92 (1H, d, J=8.4 Hz), 7.16 (1H, s), 7.26 (1H,d, J=8.4 Hz), 7.72 (1H, s), 7.97 (1H, d, J=8.8 Hz); ¹³C NMR (125 MHz,CDCl₃): δ 56.0 (3×C), 60.9, 61.7, 107.4, 108.9, 109.8, 111.3, 118.6,118.8, 121.0, 123.2, 127.8, 135.0, 141.9, 149.2, 149.7, 152.9, 155.6. IR(KBr) 3005, 2940, 2214, 1599, 1520 cm⁻¹. EIMS m/z (rel int) 355 (100,M⁺). Anal. Calcd for C₂₀H₂₁NO₅: C, 67.59; H, 5.96; N, 3.94. Found: C,67.43; H, 5.80; N, 4.00.

(Z)-2-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenypacrylonitrile (17b)

Yield 90%; pale yellow granule, mp 129-130° C. (hexane-CHCl₃) (S.Yamashita, N. Kurono, H. Senboku, M. Tokuda, K.. Orito, Eur. J. Org.Chem. 2009, 8, 1173-1180; mp 128-130° C).

¹H NMR (500 MHz, CDCl₃): δ 3.87 (3H, s), 3.92 (3H, s), 3.96 (3H, s),6.91 (1H, d, J=8.5 Hz), 6.97 (2H, d, J=8.6 Hz), 7.13 (1H, s), 7.23 (1H,d, J=8.5 Hz), 7.36 (1H, s), 7.86 (2 H, d, J=8.6 Hz); ¹³C NMR (125 MHz,CDCl₃): δ 55.4, 56.0 (2×C), 108.4, 108.7, 111.3, 114.3 (2×C), 118.6,118.7, 126.6, 127.7, 130.9 (2×C), 140.1, 149.2, 149.7, 161.1. IR (KBr)3004, 2968, 2210, 1603, 1514 cm⁻¹. EIMS m/z (rel int) 295 (100, M⁺).Anal. Calcd for C₁₈H₁₇NO₃: C, 73.20;H, 5.80; N, 4.74. Found: C, 73.40;H,6.08; N, 4.36.

(Z)-2-(3,4-Dimethoxyphenyl(3-methoxyphenyl)acrylonitrile (17c)

Yield 92%; pale yellow plate, mp 113-114° C. (hexane-EtOAc). ¹H NMR (500MHz, CDCl₃): δ 3.87 (3H, s), 3.92 (3H, s), 3.96 (3H, s), 6.91 (1H, d,J=8.3 Hz), 6.97 (1H, d, J=7.7 Hz), 7.14 (1H, s), 7.26 (1H, d, J=8.3 Hz),7.35 (1H, d, J=7.7 Hz), 7.40 (2H, br s), 7.47 (1H, s); ¹³C NMR (125 MHz,CDCl₃): δ 55.3, 56.0 (2×C), 108.8, 111.3, 111.5, 113.4, 116.5, 118.1,119.1, 121.9, 127.2, 129.8, 135.1, 140.3, 149.3, 150.1, 159.8. IR (KBr)3005, 2940, 2835, 2218, 1597, 1516 cm⁻¹. EIMS m/z (rel int) 295 (100,M⁺). HREIMS m/z calcd for C₁₈H₁₇NO₃: 295.1208; found: 295.1203 [M]⁺.Anal. Calcd for C₁₈H₁₇NO₃: C, 73.20; H, 5.80; N, 4.74. Found: C, 73.08;H, 5.46; N, 4.65.

(Z)-3-(3,4,5-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylonitrile(17d)

Yield 95%; yellow needle, mp 159-160° C. (hexane-EtOAe) (J. W.Clark-Lewis, J. Chem. Soc. 1960, 2433-2436; mp 169-170° C.).

¹H NMR (500 MHz, CDCl₃): δ 3.93 (12H, s), 3.97 (3H, s), 6.92 (1H, d,J=8.3 Hz), 7.14 (1H, s), 7.17 (2H, s), 7.25 (1H, d, J=8.3 Hz), 7.34 (1H,s); ¹³C NMR (125 MHz, CDCl₃): δ 56.0, 56.1, 56.2 (2×C), δ 1.0, 106.5(2×C), 108.7, 110.3, 111.3, 118.4, 119.0, 127.3, 129.2, 139.9, 140.3,149.3, 150.0, 153.2 (2×C). IR (KBr) 3084, 2949, 2220, 1582, 1517 cm⁻¹.EIMS m/z (rel int) 355 (100, M⁺). Anal. Calcd for C₂₀H₂₁NO₅: C,67.59;1-1, 5.96; N, 3.94. Found: C, 67.30; H, 6.11; N, 3.79.

(Z)-2-(3,4,5-Trimethoxyphenyl)-3-(3,4-dimethoxy⁻phenyl)acrylonitrile(17e)

Yield 90%; pale yellow needle, mp 137-138° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.89 (3H, s), 3.94 (6H, s), 3.95 (3H, s),3.97 (3H, s), 6.85 (2H, s), 6.93 (1H, d, J=8.5 Hz), 7.37 (1H, dd, J=8.5,1.8 Hz), 7.38 (1H, s), 7.67 (1H, d, J=1.8 Hz); ¹³C NMR (125 MHz, CDCl₃):δ 55.9, 56.0, 56.3 (2×C), 60.9, 103.2 (2×C), 108.6, 110.8, 110.9, 118.6,124.1, 126.6, 130.4, 138.8, 141.6, 149.0, 151.1, 153.5 (2×C). IR (KBr)3007, 2943, 2212, 1585, 1518 cm⁻¹. EIMS m/z (rel int) 355 (100, M⁺).Anal. Calcd for C₂₀H₂₁N₀₅: C, 67.59; H, 5.96; N, 3.94. Found: C, 67.57;H, 5.96; N, 3.90.

(Z)-3-(3,4-DimethoxyphenyI)-2-(3-methoxyphenyl)acrylonitrile (17f)

Yield 94%; yellow plate, mp 107-108° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.87 (3H, s), 3.95 (3H, s), 3.97 (3H, s),6.92 (1H, d, J=8.5 Hz), 6.93 (1H, d, J=8.5 Hz), 7.17 (1H, s), 7.25 (1H,d, J=8.5 Hz), 7.32-7.38 (2H, m), 7.45 (1H, s), 7.71 (1H, s); ¹³C NMR(125 MHz, CDCl₃): δ 55.3, 55.9 (2×C), 108.5, 110.8, 110.9, 111.4, 114.2,118.2, 118.6, 124.4, 126.6, 130.0, 136.2, 142.3, 149.0, 151.1, 160.0. IR(KBr) 3017, 2951, 2832, 2207, 1593, 1512 cm⁻¹. EIMS m/z (rel int) 295(100, M⁺). HREIMS m/z calcd for C₁₈H₁₇NO₃: 295.1208; found: 295.1207[M]⁺. Anal. Calcd for C₁₈H₁₇NO₃: C, 73.20; H, 5.80; N, 4.74. Found: C,73.04; H, 5.46; N, 4.66.

(Z)-3-(3,4-Dimethoxyphenyl)-2-(4-methoxyphenyl)acrylonitrile (17g)

Yield 88%; pale yellow granule, mp 109-110° C. (hexane-EtOAc) (T. H.Chuang, W. Y. Chang, C. F. Li, Y. C. Wen, C. C. Tsai, J. Org. Chem.2011, 76, 9678-9686.; mp 109-110° C.). 1H NMR (500 MHz, CDCl₃): δ 3.84(3H, s), 3.93 (3H, s), 3.96 (3H, s), 6.91 (1H, d, J=8.4 Hz), 6.95 (2H,d, J=8.8 Hz), 7.31-7.34 (2H, m), 7.58 (2H, d, J=8.7 Hz), 7.67 (1H, s);13C NMR (125 MHz, CDCl₃): δ 55.4, 55.9, 56.0, 108.3, 110.6, 110.9, 114.4(2×C), 118.7, 123.9, 126.9, 127.0 (2×C), 127.3, 140.1, 149.0, 150.8,160.1. IR (KBr) 3046, 2998, 2210, 1604, 1515 cm⁻¹. EIMS m/z (rel int)295 (100, M⁺). Anal. Calcd for C₁₈H₁₇NO₃: C, 73.20;H, 5.80; N, 4.74.Found: C, 73.40; H, 5.70; N, 4.50.

(Z)-2-(2,3,4-Trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylonitrile(17h)

Yield 67%; pale yellow needle, mp 134-135° C.

¹H NMR. (500 MHz, CDCl₃): δ 3.89 (3H, s), 3.90 (3H, s), 3.94 (3H, s),3.97 (3H, s), 3.99 (3H, s), 6.70 (1H, d, J=8.7 Hz), 6.91 (1H, d, J=8.5Hz), 7.11 (1H, d, J=8.7 Hz), 7.29 (1H, s), 7.31 (1H, dd, J=8.5, 1.8 Hz),7.72 (1H, d, J=1.8 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 55.9, 56.0 (2×C),60.8, 60.9, 105.4, 107.4, 110.7, 110.9, 119.0, 123.0, 123.8, 124.1,127.1, 142.4, 144.8, 149.0, 150.8, 151.6, 154.5. IR (KBr) 3140, 2938,2214, 1596, 1520 cm⁻¹. EIMS m/z (rel int) 355 (100, M⁺). Anal. Calcd forC₂₀H₂₁NO₅: C, 67.59; H, 5.96; N, 3.94. Found: C, 67.28; H, 6.01; N,3.76.

(Z)-2,3-Bis(3,4-dimethoxyphenypacrylonitrile (17i)

Yield 97%; bright yellow granule, mp 155-156° C. (hexane-EtOAc) (T. H.Chuang, W. Y. Chang, C. F. Li, Y. C. Wen, C. C. Tsai, J. Org. Chem.2011, 76, 9678-9686; mp 155-156° C.). ¹H NMR (500 MHz, CDCl₃): δ 3.93(3H, s), 3.94 (3H, s), 3.96 (3H, s), 3.97 (3H, s), 6.91 (1H, d, J=8.4Hz), 6.92 (1H, d, J=8.4 Hz), 7.13 (1H, s), 7.23 (1H, d, J=8.4 Hz),7.34-7.35 (2H, m), 7.67 (1H, s); ³C NMR (125 MHz, CDCl₃): δ 55.93,55.95, 55.98, 56.0, 108.5, 108.6, 110.7, 110.9, 111.3, 118.7 (2×C),123.9, 126.8, 127.6, 140.4, 149.0, 149.2, 149.7, 150.8. IR (KBr) 3000,2940, 2837, 2209, 1591, 1522 cm ⁻¹. EIMS m/z (rel int) 325 (100, M⁺).Anal. Calcd for C₁₉H₁₉NO₄: C, 70.14; H, 5.85; N, 4.31. Found: C, 70.24;H, 5.76; N, 4.55.

-   2. Synthesis of (E)-2,3-diphenylacrylaldehydes 16a-i

Typical procedure for the synthesis of (E)-2,3-diphenylacrylaldehydes 16according to the literature. [T. H. Chuang, W Y. Chang, C. F. Li, Y. C.\Ven, C. C. Tsai, J. Org. Chem. 2011, 76, 9678-9686] A solution ofDMAL-H (1.1 M in cyclohexane, 6.4 mL, 7 mmol) was added to a solution of(Z)-2,3-diphenylacrylonitriles 17a-i (5mmol) in CH₂Cl₂ (50 ml), and themixture was stirred at −78° C. for 30 min. The mixture was warmed to RTand stirred for 3 h. The resulting solution was quenched with 10% HClsolution (30 mL), and the mixture was stirred for 30 min. The H₂O layerwas extracted with CH₂Cl₂ (3×50 mL) and the combined extract was washedwith H₂O (3×30 mL), dried over anhydrous MgSO₄, and filtered. Thefiltrate was concentrated and the residue was purified by columnchromatography over silica gel by eluting with a mixture of hexane/EtOAc(3:1 v/v), affording pure E-(2,3)-dikphenylacrylaldehyde (E)-16a-j asthe major product. The complete spectral data of these compounds aregiven below.

(E)-3-(2,3,4-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylaldehyde(16a)

Yield 69%; white needle, mp 89-90° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.80 (3H, s), 3.82 (3H, s), 3.88 (3H, s),3.91 (3H, s), 4.01 (3H, s), 6.40 (1H, d, J=9.0 Hz), 6.70 (1H, d, J=1.8Hz), 6.72 (1H, d, J=9.0 Hz), 6.77 (1H, dd, J=8.2, 1.8 Hz), 6.92 (1H, d,J=8.2 Hz), 7.67 (1H, s), 9.75 (1H, s); ¹³C NMR (125 MHz, CDCl₃); δ 55.8(3×C), 60.8, 61.7, 106.9, 111.5, 112.4, 120.8, 121.8, 125.6, 126.1,140.0, 141.8, 144.2, 148.7, 149.1, 153.5, 155.2, 194.2. IR (KBr) 3005,2944, 2839, 2730, 1687, 1578, 1515 cm⁻¹. EIMS m/z (rel int) 358 (75,M⁺), 327 (100). Anal. Calcd for C₂₀H₂₂O₆: C, 67.03; H, 6.19. Found C,67.31; H, 6.55.

(E)-2-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)acrylaldehyde (16b)

Yield 75%; yellow needle, mp 114-115° C. (hexane-EtOAc) (P. A. Grieco,D. T. Parker, J. Org. Chem. 1988, 53, 3325-3330; mp 110-112° C).

¹H NMR (500 MHz, CDCl₃): δ 3.80 (3H, s), 3.81 (3H, s), 3.93 (3H, s),6.70 (1H, d, J=1.0 Hz), 6.76-6.79 (3H, m), 6.94 (1H, d, J=8.2 Hz), 7.21(2H, d, J=8.8 Hz), 7.30 (1H, s), 9.71 (1H, s); ¹³C NMR (125 MHz, CDCl₃):δ 55.3, 55.8, 55.9, 111.7, 112.3, 114.0 (2×C), 121.8, 126.1, 126.8,132.7 (2×C), 139.5, 148.9, 149.3, 150.0, 161.2, 194.1. IR (KBr) 3094,2944; 2827; 2705, 1669, 1585, 1506 cm⁻¹. EIMS m/z (rel int) 298 (100,M⁺). Anal. Calcd for C₁₈H₁₈O₄: C, 72.47; H, 6.08. Found: C, 72.45; H,6.25.

(E)-2-(3,4-Dimethoxyphenyl)-3-(3-methoxyphenypacrylaldehyde (16c)

Yield 64%; white needle, mp 94-95° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.59 (3H, s), 3.79 (3H, s), 3.90 (3H, s),6.71 (1H, s), 6.78 (1H, s), 6.79 (1H, d, J=8.0 Hz), 6.85 (1H, d, J=8.0Hz), 6.87 (1H, d, J=8.0 Hz), 6.93 (1H, d, J=8.0 Hz), 7.17 (1H, t, J=8.0Hz), 7.33 (1H, s), 9.75 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 54.9, 55.8(2×C), 111.5, 112.4, 114.9, 116.6, 121.9, 123.6_(;) 125.6, 129.4, 135.3,141.6, 149.0, 149.2, 149.8, 159.3, 194.1 . IR (KBr) 3036, 2962, 2835,2712, 1674, 1628, 1597, 1516 cm⁻¹. ElMS m/z (rel int) 298 (100, M⁺).HREIMS m/z calcd for C₁₈H₁₈O₄: 298.1205; found.: 298.1201. Anal. Calcdfor C₁₈H₁₈O₄: C, 72.47; H, 6.08. Found: C, 72.41; H, 6.07.

(E)-3-(3,4,5-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)acrylaldehyde(16d)

Yield 75%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 3.62 (6H, s), 3.82 (3H, s), 3.85 (3H, s),3.90 (3H, s), 6.54 (2H, s), 6.74 (1H, s), 6.81 (1H, d, J=8.1 Hz), 6.96(1H, d, J=8.1 Hz), 7.28 (1H, s), 9.74 (1H, s); ¹³C NMR (125 MHz, CDCl₃):δ 55.8 (2×C), 55.9, 56.0, 60.9, 108.3 (2×C), 111.7, 112.5, 122.0, 126.0,129.2, 140.0, 140.8, 149.1, 149.5, 149.9, 152.8 (2×C), 193.9. IR (KB)3009, 2938, 2833, 2712, 1678, 1576, 1514 cm⁻¹. EIMS m/z (rel int) 358(100, M⁺). Anal. Calcd for C₂₀H₂₂O₆: C, 67.03; H, 6.19. Found: C,66.79;H, 5.90.

(E)-2-(3,4,5-Trimethoxypheny0-3-(3,4-dimethoxyphenypacrylaldehyde (16e)

Yield 70%; white needle, mp 133-134° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.52 (3H, s), 3.81 (6H, s), 3.87 (3H, s),3.89 (3H, s), 6.44 (2H, s), 6.69 (1H, s), 6.81 (1H, d, J=8.2 Hz), 6.99(1H d, J=8.2 Hz), 7.31 (1H, s), 9.71 (1H, s); ¹³C NMR. (125 MHz, CDCl₃):δ 55.2, 55.8, 56.1 (2×C), 60.7, 106.3 (2×C), 110.7, 112.3, 126.2, 126.7,129.5, 137.8, 139.8, 148.5, 150.3, 151.2, 153.9 (2×C), 193.6. IR (KBr)3001, 2940; 2833; 2733, 1672, 1582, 1512 cm⁻¹. EIMS m/z (rel int) 358(100, M⁺). Anal. Calcd for C₂₀H₂₂O₆: C, 67.03; H, 6.19. Found: C, 66.90;H, 6.49.

(E)-3-(3,4-Dimethoxyphenyl)-2-(3-methoxyphenyl)aerylaldehyde (16f)

Yield 84%; pale yellow needle, mp 90-92° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl3): δ 3.45 (3H, s), 3.77 (3H, s), 3.86 (3H, s),6.66 (1H, s), 6.76 (1H, s), 6.78 (1H, d, J=8.0 Hz), 6.81 (1H, d, J=8.0Hz), 6.91 (1H, d, J=8.0 Hz), 6.97 (1H, d, J=8.0 Hz), 7.30 (1H, s), 7.35(1H, t, J=8.0 Hz), 9.71 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 55.1, 55.2,55.8, 110.6, 112.4, 113.9, 114.7, 121.7, 126.0, 126.8, 130.0, 135.4,139.7, 148.4, 149.9, 151.0, 160.1, 193.4. IR (KBr) 3082, 2959, 2835,2723, 1677, 1620, 1582, 1516 cm⁻¹. EIMS m/z (rel int) 298 (45, M⁺), 137(100). HREIMS m/z calcd for C₁₈H₁₈O₄: 298.12058; found: 295.1210 [M]⁺.Anal. Calcd for C₁₈H₁₈O₄: C, 72.47; H, 6.08. Found: C, 72.19; H, 6.25.

(E)-3-(3,4-DimethoxyphenyI)-2-(4-methoxyphenyl)aerylaldehyde (16g)

Yield 70%; pale yellow granule, alp 101-102° C. (hexane-EtOAc) (T. H.Chuang, W. Y. Chang, C. F. Li, Y. C. Wen, C. C. Tsai, J. Org. Chem.2011, 76, 9678-9686; nip 101-102° C.).

¹H NMR (500 MHz, CDCl₃): δ 3.50 (3H, s), 3.83 (3H, s), 3.88 (3H, s),6.70 (1H, s), 6.79 (1H, d, J=8.4 Hz), 6.97-6.99 (3H, m), 7.16 (2H, d,J=8.4 Hz), 7.29 (1H, s), 9.72(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 55.2,55.3, 55.8, 110.6, 112.4, 114.4 (2×C), 125.7, 125.8, 127.1, 130.8 (2×C),139.5, 148.3, 150.1, 150.9, 159.5, 194.0. IR (KBr) 3056, 2997, 2840,1666, 1600, 1515 cm⁻¹. EIMS m/z (rel int) 298 (100, M⁺). Anal. Calcd forC₁₈H₁₈O₄: C, 72.47; 6.08. Found: C, 72.14; H, 6.10.

(E)-2-(2,3,4-TrimethoxyphenyI)-3-(3,4-dimethoxyphenypacrylaldehyde (16h)

Yield 60%; yellow syrup.

¹H NMR. (500 MHz, CDCl₃): δ 3.52 (3H, s), 3.73 (3H, s), 3.86 (3H, s),3.89 (6H, s), 6.69 (114, s), 6.73-6.82 (3H, m), 6.97 (1H, d, 7.6 Hz),7.39 s), 9.72 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 55.2, 55.9, 56.1,60.9, 61.0, 108.1, 110.7, 112.1, 121.0, 124.9, 125.7, 127.3, 136.9,142.8, 148.5, 150.4, 151.0, 151.7, 154.1, 193.9. IR (KBr) 3005, 2938,2837, 2710, 1678, 1595, 1514 cm⁻¹. EIMS m/z (rel int) 358 (100, M⁺).Anal. Caled for C₂₀H₂₂O₆: C, 67.03; H, 6.19. Found: C, 66.73; H, 5.95.

(E)-2,3-Bis(3,4-dimethoxyphenypacrylaldehyde (1.6i)

Yield 91%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 3.52 (3H, s), 3.82 (3H, s), 3.88 (3H, s),3.91 (3H, s), 6.73-6.82 (4H, m), 6.95-6.98 (2H, m), 7.30 (1H, s), 9.72(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 55.3, 55.8, 55.9, 56.0, 110.6,111.7, 112.5 (2×C), 121.9, 125.7, 126.2, 126.9, 139.6, 148.4, 148.9,149.4, 150.1, 151.0, 193.9. IR (KBr) 3005, 2938, 2837, 2710, 1678, 1595,1514 cm⁻¹. EIMS m/z (rel int) 358 (100, M⁺). Anal. Calcd for C₂₀H₂₂O₆:C, 67.03; H, 6.19. Found: C, 66.73; H, 5.95.

-   3. Synthesis of α-iminonitriles14a-i and 15a-i

Typical procedure for the synthesis ofot-iminonitriles 14a-i and 15a-i.A suspension of (E)-2,3- diphenylacrylaldehydes (E)-16a-i (2 mmol),pent-4-enylamine (S1) (4 mmol) (J. Y. Kim, T. Livinghouse, Org. Lett.2005, 7, 1737-1739) (or hex-5-enylamine (S2) (Z. K. M. A. E. Samii, M.I. A. Ashmawy, J. M. :Mellor, J. Chem. Soc., Perkin Trans. 1 1988,2517-2522), and MgSO4 (3 mmol) in anhydrous CH₂Cl₂ (8 mL) in a sealedtube was heated at 45° C. for 24 h. After cooling, the reaction mixturewas filtered and concentrated under reduced pressure, affording theSchiff base intermediate quantitatively. Then, TMSCN (2.2 mmol) wasadded to a solution of the Schiff base in anhydrous CH₃CN (8 mL) at RT,and the mixture was stirred for 1 h. IBX [M. Frigerio, M. Santagostino,S. Sputore, J. Org. Chem. 1999, 64, 4537-4538] (2.2 mmol) and TBAB (2.2mmol) were added and stirred for 30 min. The solvent was evaporated invacuo and the residue was purified by short column chromatography oversilica gel by eluting with a mixture of hexane/EtOAc (4:1 v/v),affording pure (3E)-2-(4-pentenylimino)-3,4-diphenyl-3-butenenitrile14a-i (or (3E)-2-(5-hexenylimino)-3,4-diphenyl-3-butenenitrile 15a-i).The complete spectral data of these compounds are given below.

(3E)-4-(2,3,4-Trimethoxy⁻phenyl)-3-(3,4-dimethoxyphenyl)-2-(4-pentenylimino)-3-butenenitrile(14a)

Yield 80%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.79 (2H, quintet, J=7.2 Hz), 2.13 (2H, q,J=7.2 Hz), 3.77 (3H, s), 3.79 (3H, s), 3.87 (3H, s), 3.89 (2H, t, J=7.2Hz), 3.91 (3H, s), 3.99 (3H, s), 4.99 (1H, dd, J=10.2, 1.8 Hz), 5.03(1H, dd, J=17.1, 1.8 Hz), 5.81 (1H, ddt, J=17.1, 10.2, 7.2 Hz), 6.34(1H, d, J=8.9 Hz), 6.41 (1H, d, J=8.9 Hz), 6.66 (1H, d, J=1.9 Hz), 6.71(1H, dd, J=8.2, 1.9 Hz), 6.88 (1H, d, J=8.2 Hz), 7.79 (1H, s); ¹³C NMR(125 MHz, CDCl₃): δ 29.6, 31.5, 55.8, 55.9, 56.0, 58.2, 60.9, 61.6,107.0, 109.7, 111.3, 113.2, 115.2, 121.8, 122.5, 125.2, 127.8, 134.2,136.6, 137.8, 141.9, 145.4, 148.8, 149.0, 153.4, 154.5. IR (KBr) 3021,2940, 2216, 1576, 1516 cm⁻¹. EIMS m/z (rel int) 450 (60, M⁺), 417 (100);HREIMS m/z calcd for C₂₆H₃₀NO₅: 450.2155; found: 450.2158 [M]⁺.

(3E)-3-(3,4-Dimetlioxyphenyl)-4-(4-methoxyphenyl)-2-(4-pentenylimino)-3-butenenitrile(14b)

Yield 78%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.78 (2H, quintet, J=7.0 Hz), 2.12 (2H, q,J=7.0 Hz), 3.77 (3H, s), 3.78 (3H, s), 3.89 (2H, t, J=7.0 Hz), 3.92 (3H,s), 4.98 (1H, d, J=10.2 Hz), 5.02 (1H, d, J=17.0 Hz), 5.81 (1H, ddt,J=17.0, 10.2, 7.0 Hz), 6.66 (1H, d, J=1.4 Hz), 6.71 (2H, d, J=8.7 Hz),6.72 (1H, dd, J=8.2, 1.4 Hz), 6.90 (1H, d, J=8.2 Hz), 7.00 (2H, d, J=8.7Hz), 7.46 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 29.6, 31.4, 55.2, 55.7,55.8, 58.2, 109.7, 111.5, 113.0 (2×C), 113.8, 115.2, 122.4, 127.4,127.6, 132.2 (2×C), 135.9, 137.8, 139.6, 145.1, 148.8, 149.2, 160.2. IR(KBr) 3075, 2936, 2214, 1605, 1574, 1512 cm⁻¹. EIMS m/z (rel int) 390(100, M⁺); HREMS rn/z calcd for C₂₄H₂₆NO₃: 390.1943; found: 390.1941[M]⁺.

(3E)-3-(3,4-Dimethoxyphenyl)-4-(3-methoxyphenyl)-2-(4-pentenylimino)-3-butenenitrile(14c)

Yield 81%; yellow syrup.

¹ H NMR (500 MHz, CDCl₃): δ 1.80 (2H, quintet, J=7.0 Hz), 2.12 (2H, q,J=7.0 Hz), 3.57 (3H, s), 3.76 (3H, s), 3.90 (3H, s), 3.91 (2H, t, J=7.0Hz), 4.99 (1H, dd, J=10.2, 1.7 Hz), 5.03 (1H, dd, J=17.0, 1.7 Hz), 5.81(1H, ddt, J=17.0, 10.2, 7.0 Hz), 6.58 (1H, t, J=1.9 Hz), 6.67 (1H, d,J=1.9 Hz), 6.71 (1H, dd, J=8.0, 1.9 Hz), 6.73 (1H, dd, J=8.0, 1.9 Hz),6.77 (1H, dd, J=8.0, 1.9 Hz), 6.89 (1H, d, J=8.0 Hz), 7.11 (1H, t, J=8.0Hz), 7.49 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 29.5, 31.4, 54.9, 55.8,55.9, 58.4, 109.6, 111.4, 113.2, 114.7, 115.3, 115.6, 122.5, 123.3,127.3, 129.2, 136.0, 137.7, 138.1, 139.7, 145.0, 149.0, 149.2, 159.2. IR(KBr) 3075, 2924, 2214, 1578, 1516 cm⁻¹. EIMS m/z (rel int) 390 (95,M⁺), 165 (100); HREIMS m/z calcd for C₂₄H₂₆N₂O₃: 390.1943; found:390.1948 [M]⁺.

(3E)-4-(3,4,5-Trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-2-(4-pentenylimino)-3-butenenitrile(14d)

Yield 80%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.79 (2H, quintet, J=7.02 Hz), 2.12 (2H, q,J=7.0 Hz), 3.59 (6H, s), 3.80 (3H, s), 3.82 (3H, s), 3.89 (3H, s), 3.91(2H, t, J=7.0 Hz), 4.99 (1H, dd, J=10.2, 1.2 Hz), 5.03 (1H, dd, J=17.1,1.2 Hz), 5.81 (1H, ddt, J=17.1, 10.2, 7.0 Hz), 6.34 (2H, s), 6.70 (1H,d, J=1.9 Hz), 6.76 (1H, dd, J=8.2, 1.9 Hz), 6.93 (1H, d, J=8.2 Hz), 7.43(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 29.5, 31.4, 55.8 (2×C), 55.9, 56.0,58.4, 60.9, 108.0 (2×C), 109.6, 111.6, 113.2, 115.3, 122.5, 127.6,129.9, 137.3, 137.7, 138.9, 139.8, 145.0, 149.0, 149.4, 152.7 (2×C). IR(KBr) 3022, 2938, 2216, 1578, 1518, 1504 cm⁻¹. EIMS m/z (rel int) 450(53, M⁺), 419 (100); HREIMS m/z calcd for C₂₆H₃₀N₂O₅: 450.2155; found:450.2157 [M]⁺.

(3E)-3-(3,4,5-Trimethoxyphenyl)-4-(3,4-dimethoxyphenyI)-2-(4-pentenylimino)-3-butenenitrile(14e)

Yield 86%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.80 (2H, quintet, J=7.2 Hz), 2.13 (2H, q,J=7.2 Hz), 3.51 (3H, s), 3.77 (6H, s), 3.86 (3H, s), 3.87 (3H, s), 3.91(2H, t, J=7.2 Hz), 4.99 (1H, dd, J=10.2, 1.4 Hz), 5.02 (1H, dd, J=17.1,1.4 Hz), 5.81 (1H, ddt, J=17.1, 10.2, 7.2 Hz), 6.41 (2H, s), 6.48 (1H,d, J=1.9 Hz), 6.76 (1H, d, J=8.4 Hz), 6.85 (1H, dd, J=8.4, 1.9 Hz), 7.45(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 29.6, 31.5, 55.3, 55.8, 56.2 (2×C),58.3, 60.8, 107.0 (2×C), 109.6, 110.6, 112.2, 115.2, 125.5, 127.4,130.9, 136.1, 137.7, 137.8, 139.9, 144.8, 148.3, 150.1, 153.8 (2×C). IR(KBr) 3021, 2938, 2216, 1582, 1514 cm⁻¹. EIMS m/z (rel int) 450 (83,M⁺), 435 (100); HREIMS m/z calcd for C₂₆H₃₀N₂O₅; 450.2155; found:450.2164 [M]⁺.

(3E)-4-(3,4-Dimethoxyphenyl.)-3-(3-methoxyphenyI)-2-(4-pentenylimino)-3-butenenitrile(14f)

Yield 89%; yellow syrup.

¹H NMR. (500 MHz, CDCl₃): δ 1.76 (2H, quintet, J=7.0 Hz), 2.09 (2H, q,J=7.0 Hz), 3.44 (3H, s), 3.76 (3H, s), 3.85 (3H, s), 3.88 (2H, t, J=7.0Hz), 4.97 (1H, d, J=10.2 Hz), 5.02 (1H, d, J=17.0 Hz), 5.80 (1H, ddt,J=17.0, 10.2, 7.0 Hz), 6.44 (1H, d, J=1.9 Hz), 6.72 (1H, s), 6.74 (1H,d, J=8.6 Hz), 6.78 (1H, d, J=7.9 Hz), 6.84 (1H, dd, J=8.6, 1.9 Hz), 6.91(1H, d, J=7.9 Hz), 7.34 (1H, t, J=7.9 Hz), 7.46 (1H, s); ¹³C NMR (125MHz, CDCl₃): δ 29.5, 31.4, 55.1, 55.2, 55.8, 58.2, 109.6, 110.5, 112.2,113.8, 115.1, 115.3, 122.3, 125.3, 127.4, 130.0, 136.1, 137.0, 137.8,139.7, 144.7, 148.2, 150.0, 160.1. IR (KBr) 3075, 2935, 2218, 1597,1585, 1512 cm⁻¹. EIMS m/z (rel int) 390 (100, M⁺); HREIMS m/z calcd forC₂₄H₂₆N₂O₃: 390.1943; found: 390.1940 [M]⁺.

(3E)-4-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)-2-(4-pentenylimino)-3-butenenitrile(14g)

Yield 76%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.77 (2H, quintet, J=7.2 Hz), 2.10 (2H, q,J=7.2 Hz), 3.48 (3H, s), 3.82 (3H, s), 3.85 (3H, s), 3.88 (2H, t, J=7.2Hz), 4.98 (1H, d, J=10.2 Hz), 5.02 (1H, d, J=17.2 Hz), 5.81 (1H, ddt,J=17.2, 10.2, 7.2 Hz), 6.45 (1H, d, J=1.8 Hz), 6.74 (1H, d, J=8.4 Hz),6.81 (1H, dd, J=8.4, 1.8 Hz), 6.95 (2H, d, J=8.7 Hz), 7.10 (2H, d, 8.7Hz), 7.45 s); ¹³C NMR (125 MHz, CDCl₃): δ 29.6, 31.4. 55.2, 55.3, 55.8,58.3, 109.8, 110.6, 112.4, 114.4 (2×C), 115.2, 125.1, 127.6, 127.7,131.4 (2×C), 136.1, 137.8, 139.8, 145.1, 148.3, 149.9, 159.4. IR (KBr)3009, 2955, 2218, 1639, 1612, 1570, 1508 cm⁻¹. ElMS m/z (rel int) 390(21, M⁺), 265 (100); HREIMS m/z called for C₂₄H₂₆N₂O₃: 390.1943; found:390.1951 [M]⁺.

(3E)-(2,3,4-Trimethoxyphenyl)-4-(3,4-dimethoxyphenyl)-2-(4-pentenylirino)-3-butenenitrile(14h)

Yield 78%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.75 (2H, quintet, J=7.0 Hz), 2.10 (2H, q,J=7.0 Hz), 3.52 (3H, s), 3.72 (3H, s), 3.85 (3H, s), 3.86 (3H, s), 3.87(3H, s), 3.88 (2H, t, J=7.0 Hz), 4.97 (1H, dd, J=10.2, 1.8 Hz), 5.01(1H, dd, J=17.1, 1.8 Hz), 5.79 (1H, ddt, J=17.1, 10.2, 7.0 Hz), 6.52(1H, d, J=1.9 Hz), 6.70-6.76 (3H, m), 6.84 (1H, dd, J=8.4, 1.9 Hz), 7.50(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 29.6, 31.3, 55.2, 55.8, 56.0, 58.1,60.7, 60.8, 107.8, 109.9, 110.7, 112.0, 115.1, 122.5, 125.0, 125.2,127.8, 133.3, 137.9, 139.7, 142.7, 144.8, 148.3, 149.9, 151.8, 154.1. IR(KBr) 3030, 2947, 2216, 1533 cm⁻¹. EIMS m/z (rel int) 450 (37, M⁺), 419(100); HREIMS m/z calcd for C₂₆H₃₀N₂O₅: 450.2155; found: 450.2144 [M]⁺.

(3E)-3,4-Bis(3,4-dimethoxyphenyl)-2-(4-pentenylimino)-3-butenenitrile(14i)

Yield 86%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.78 (2H, quintet, J=7.0 Hz), 2.12 (2H, q,J=7.0 Hz), 3.51 (3H, s), 3.79 (3H, s), 3.86 (3H, s), 3.88 (2H, t, J=7.0Hz), 3.89 (3H, s), 4.99 (1H, dd, J=10.2, 2.0 Hz), 5.02 (1H, dd, J=17.1,2.0 Hz), 5.81 (1H, ddt, J=17.1, 10.2, 7.0 Hz), 6.50 (1H, d, J=2.0 Hz),6.70 (1H, d, J=1.8 Hz), 6.73 (1H, d, J=8.5 Hz), 6.75 (1H, dd, J=8.3, 1.8Hz), 6.80 (1H, dd, J=8.5, 2.0 Hz), 6.92 (1H, d, J=8.3 Hz), 7.45 (1H, s);¹³C NMR (125 MHz, CDCl₃): δ 29.5, 31.4, 55.3, 55.8, 55.9 (2×C), 58.2,109.7, 110.6, 111.6, 112.5, 113.1, 115.2, 122.5, 125.0, 127.6, 127.8,136.0, 137.7, 139.8, 145.0, 148.2, 148.8, 149.4, 149.9. IR (KBr) 3001,2932, 2214, 1574, 1516 cm⁻¹. EIMS m/z (rel int) 420 (77, M⁺), 419 (100);HREIMS rn/z calcd for C₂₅H₂₈N₂O₄: 420.2049; found: 420.2047 [M]⁺.

(3E)-2-(5-Hexenylimino)-4-(2,3,4-trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-3-butenenitrile(15a)

Yield 81%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.46 (2H, quintet, J=7.1 Hz), 1.71 (2H,quintet, J=7.1 Hz), 2.09 (2H, q, J=7.1 Hz), 3.77 (3H, s), 3.79 (3H, s),3.87 (3H, s), 3.89 (2H, t, J=7.1 Hz), 3.91 (3H, s), 3.99 (3H, s), 4.95(1H, dd, J=10.1, 1.2 Hz), 5.01 (1H, dd, J=17.1, 1.2 Hz), 5.79 (1H, ddt,J=17.1, 10.1, 7.1 Hz), 6.34 (1H, J=8.9 Hz), 6.40 (1H, d, J=8.9 Hz), 6.66(1H, d, J=1.6 Hz), 6.71 (1H, dd, J=8.2, 1.6 Hz), 6.87 (1H, d, J=8.2 Hz),7.79 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 26.5, 29.8, 33.3, 55.6, 55.7,55.8, 58.6, 60.8, 61.5, 106.9, 109.6, 111.3, 113.2, 114.6, 121.7, 122.4,125.1, 127.7. 134.0, 136.5, 138.3, 141.8, 145.2, 148.7, 149.0, 153.3,154.4. IR (KBr) 3005, 2938, 2218, 1580, 1516 cm ⁻¹. EIMS m/z (rel int)464 (91, M⁺), 433 (100) HREIMS m/z calcd for C₂₇H₃₂N₂O₅: 464.2311;found: 464.2306 [M]⁺.

(3E)-2-(5-Hexenylimino)-3-(3,4-dimethoxyphenyl)-4-(4-methoxyphenyl)-3-butenenitrile(15b)

Yield 83%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.45 (2H, quintet, J=7.0 Hz), 1.69 (2H,quintet, J=7.0 Hz), 2.08 (2H, q, J=7.0 Hz), 3.76 (3H, s), 3.77 (314, s),3.89 (2H, t, J=7.0 Hz), 3.91 (3H, s), 4.95 (1H, d, J=10.2 Hz), 5.00 (1H,d, J=17.0 Hz), 5.79 (1H, ddt, J=17.0, 10.2, 7.0 Hz), 6.66 (1H, d, J=1.5Hz), 6.70 (2H, d, J=8.8 Hz), 6.71 (1H, dd, J=8.5, 1.5 Hz), 6.89 (1H, d,J=8.5 Hz), 7.00 (2H, d, J=8.8 Hz), 7.46 (1H, s); ¹³C NMR (125 MHz,CDCl₃): δ 26.5, 29.8, 33.3, 55.2, 55.7, 55.8, 58.7, 109.7, 111.4, 113.0,113.7 (2×C), 114.6, 122.3, 127.4, 127.6, 132.1 (2×C), 135.9, 138.4,139.4, 144.9, 148.8, 149.2, 160.1. IR (KBr) 3075, 2936, 2218, 1639,1605, 1581, 1512 cm⁻¹. EIMS m/z (rel int) 404 (100, M⁺); HREIMS m/zcalcd for C₂₅H₂₈N₂O₃: 404.2100; found: 404.2107 [M]⁺.

(3E)-2-(5-Hexenylimino)-3-(3,4-dimethoxyphenyl.)-4-(3-methoxyphenyl)-3-butenenitrile(15c)

Yield 83%; yellow syrup.

¹H NMR. (500 MHz, CDCl₃): δ 1.47 (2H, quintet, J=7.2 Hz), 1.71 (2H,quintet, J=7.2 Hz), 2.09 (2H, q, J=7.2H), 3.57 (3H, s), 3.76 (3H, s),3.90 (3H, s), 3.91 (2H, t, J=7.2 Hz), 4.96 (1H, d, J=10.2 Hz), 5.01 (1H,d, J=17.2 Hz), 5.77 (1H, ddt, J=17.2, 10.2, 7.2 Hz), 6.58 (1H, s), 6.66(1H, s), 6.70 (1H, d, J=8.0 Hz), 6.72 (1H, d, J=8.0 Hz), 6.77 (1H, d,J=8.0 Hz), 6.89 (1H, d, J=8.0 Hz), 7.11 (1H, t, J=8.0 Hz), 7.48 (1H, s);¹³C NMR (125 MHz, CDCl₃): δ 26.6, 29.8, 33.4, 54.9, 55.8, 55.9, 58.9,109.6, 111.4, 113.2, 114.7, 114.8, 115.6, 122.5, 123.3, 127.3, 129.2,136.1, 138.1, 138.4, 139.6, 144.8, 149.0, 149.2, 159.2. IR (KBr) 3075,2932, 2218, 1578, 1516 cm⁻¹. EIMS m/z (rel int) 404 (59, M⁺), 165 (100);HREIMS m/z calcd for C₂₅H₂₈N₂O₃: 404.2100; found: 404.2101 [M]⁺.

(3E)-2-(5-Hexenylimino)-4-(3,4,5-trimethoxyphenyl)-3-(3,4-dimethoxy⁻phenyl)-3-butenenitrile(15d).

Yield 80%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.45 (2H, quintet, J=7.2 Hz), 1.71 (2H,quintet, J=7.2 Hz), 2.09 (2H, q, J=7.2 Hz), 3.59 (6H, s), 3.79 (3H, s),3.82 (3H, s), 3.89 (3H, s), 3.91 (2H, t, J=7.2 Hz), 4.95 (1H, dd,J=10.2, 1.9 Hz), 5.01 (1H, dd, J=17.1, 1.9 Hz), 5.79 (1H, ddt, J=17.1,10.2, 7.2 Hz), 6.34 (2H, s), 6.69 (1H, d, J=1.9 Hz), 6.75 (1H, dd,J=8.2, 1.9 Hz), 6.93 (1H, d, J=8.2 Hz), 7.42 (1H, s); ¹³C NMR (125 MHz,CDCl₃): δ 26.6, 29.8, 33.4, 55.8 (2×C), 55.9, 56.0, 58.9, 60.9, 107.9(2×C), 109.7, 111.6, 113.2, 114.8, 122.5, 127.6, 130.0, 137.3, 138.4,138.9, 139.7, 144.8, 149.0, 149.4, 152.7 (2×C). IR (KBr) 3021, 2936,2218, 1576, 1506 cm⁻¹. EIMS m/z (rel int) 464 (100, M⁺); HREIMS m/zcalcd for C₂₇H₃₂N₂O₅: 464.2311; found: 464.2307 [M]⁺.

(3E)-2-(5-Hexenylimino)-3-(3,4,5-trimethoxyphenyl)-4-(3,4-dimethoxyphenyl)-3-butenenitrile(15e)

Yield 82%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.46 (2H, quintet, J=7.0 Hz), 1.71 (2H,quintet, J=7.0 Hz), 2.09 (2H, q, J=7.0 Hz), 3.51 (3H, s), 3.77 (6H, s),3.87 (6H, s), 3.91 (2H, t, J=7.0 Hz), 4.95 (1H, d, J=10.2 Hz), 5.00 (1H,d, J=17.3 Hz), 5.79 (1H, ddt, J=17.3, 10.2, 7.0 Hz), 6.41 (2H, s), 6.48(1H, s), 6.76 (1H, d, J=8.4 Hz), 6.84 (1H, d, J=8.4 Hz), 7.45 (1H, s);¹³C NMR (125 MHz, CDCl₃): δ 26.6, 29.9, 33.4, 55.3, 55.8, 56.2 (2×C),58.8, 60.8, 107.0 (2×C), 109.6, 110.6, 112.2, 114.7, 125.2, 127.4,130.9, 136.1, 137.8, 138.4, 139.8, 144.7, 148.3, 150.1, 153.8 (2×C). IR(KBr) 3005, 2938, 2218, 1570, 1512 cm⁻¹. EIMS m/z (rel int) 464 (100,M⁺); HREIMS m/z calcd for C₂₇H₃₂N₂O₅: 464.2311; found: 464.2318 [M]⁺.

(3E)-2-(5-Hexenylimino)-4-(3,4-dimethoxyphenyl)-3-(3-methoxyphenyl)-3-butenenitrile(15!)

Yield 86%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.43 (2H, quintet, J=7.0 Hz), 1.67 (2H,quintet, J=7.0 Hz), 2.07 (2H, q, J=7.0 Hz), 3.44 (3H, s), 3.76 (3H, s),3.85 (3H, s), 3.88 (2H, t, J=7.0 Hz), 4.94 (1H, d, J=10.2 Hz), 5.00 (1H,d, J=17.2 Hz), 5.78 (1H, ddt, J=17.2, 10.2, 7.0 Hz), 6.43 (1H, d, J=1.7Hz), 6.72 (1H, s), 6.74 (1H, d, J=8.4 Hz), 6.78 (1H, d, J=7.9 Hz), 6.84(1H, dd, J=8.4, 1.7 Hz), 6.91 (1H, d, J=7.9 Hz), 7.35 (1H, t, J=7.9 Hz),7.46 (1H, s); NMR (125 MHz, CDCl₃): δ 26.5, 29.8, 33.3, 55.2, 55.3,55.8, 58.8, 109.6, 110.6, 112.4, 113.9, 114.6, 115.4, 122.3, 125.3,127.5, 130.0, 136.2, 137.1, 138.5, 139.6, 144.6, 148.3, 150.0, 160.1. IR(KBr) 3075, 2936, 2218, 1574, 1512 cm⁻¹. EIMS m/z (rel int) 404 (100,M⁺); HREIMS m/z calcd for C₂₅H₂₈N₂O₃: 404.2100; found: 404.2095 [M]⁺.

(3E)-2-(5-flexenylimino)-4-(3,4-dimethoxyphenyl)-3-(4-methoxyphenyl)-3-butenenitrile(15g)

Yield 83%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.44 (2H, quintet, J=7.0 Hz), 1.68 (2H,quintet, J=7.0 Hz), 2.08 (2H, q, J=7.0 Hz), 3.47 (3H, s), 3.82 (3H, s),3.85 (3H, s), 3.88 (2H, t, J=7.0 Hz), 4.95 (1H, d, J=10.1 Hz), 5.00 (1H,d, J=17.3 Hz), 5.79 (1H, ddt, J=17.3, 10.1, 7.0 Hz), 6.45 (1H, s), 6.73(1H, d, J=8.4 Hz), 6.81 (1H, d, J=8.4 Hz), 6.95 (2H, d, J=7.5 Hz), 7.10(2H, t, J=7.5 Hz), 7.45 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 26.5, 29.7,33.3, 55.1, 55.2, 55.7, 58.7, 109.7, 110.5, 112.3, 114.3 (2×C), 1114.76,125.0, 127.5, 127.7, 131.3 (2×C), 136.0, 138.4, 139.6, 149.9, 148.1,149.7, 159.3. IR (KBr) 3075, 2932, 2214, 1639, 1609, 1574, 1512 cm ⁻¹.EIMS m/z (rel int) 404 (100, M⁺); HREIMS m/z calcd for C₂₅H₂₈N₂O₃:404.2100; found: 404.2103 [M]⁺.

(3E-2-(5-11exenylimino)-3-(2,3,4-trimethoxyphenyl)-4-(3,4-dimethoxyphenye-3-butenenitrile(15h)

Yield 75%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.44 (2H, quintet, J=7.3 Hz), 1.67 (2H,quintet, J=7.3 Hz), 2.06 (2H, q, J=7.3 Hz), 3.52 (3H, s), 3.72 (3H, s),3.84 (3H, s), 3.86 (3H, s), 3.88 (3H, s), 3.89 (2H, t, J=7.3 Hz), 4.94(1H, dd, J=10.2, 1.3 Hz), 4.99 (1H, dd, J=17.1, 1.3 Hz), 5.78 (1H, ddt,J=17.1, 10.2, 7.3 Hz), 6.52 (1H, d, J=1.9 Hz), 6.69-6.77 (3H, m), 6.84(1H, dd, J=8.4, 1.9 Hz), 7.50 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 26.5,29.9, 33.4, 55.2, 55.8, 56.0, 58.7, 60.7, 60.8, 107.8, 109.9, 110.7,112.0, 114.6, 122.5, 125.0, 125.2, 127.9, 133.2, 138.5, 139.7, 142.7,144.7, 148.3, 149.9, 151.8, 154.1. IR (KBr) 3019, 2936, 2218, 1578, 1516cm⁻¹. EIMS m/z (rel int) 464 (41, M⁺), 433 (100); HREIMS m/z calcd forC₂₇H₃₂N₂O₅: 464.2311; found: 464.2303 [m]⁺.

(3E)-2-(5-Hexenylimino)-3,4-bis(3,4-dimethoxyphenyl)-3-butenenitrile(15i).

Yield 85%; yello)A^(,) syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.45 (2H, quintet; J=7.2 Hz), 1.70 (2H,quintet, J=7.2 Hz), 2.08 (2H, q, J=7.2 Hz), 3.51 (3H, s), 3.79 (3H, s),3.85 (3H, s), 3.89 (2H, t, J=7.2 Hz), 3.90 (3H, s), 4.95 (1H, d, J=10.1Hz), 5.00 (1H, d, J=17.1 Hz), 5.79 (1H, ddt, J=17.1, 10.1, 7.2 Hz), 6.50(1H, d, J=1.9 Hz), 6.69 (1H, d, J=1.9 Hz), 6.73 (1H, d, J=8.4 Hz), 6.75(1H, dd, J=8.2, 1.9 Hz), 6.79 (1H, dd, J=8.4, 1.9 Hz), 6.92 (1H, d,J=8.2 Hz), 7.45 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 26.6, 29.8, 33.4,55.3, 55.8, 55.9 (2×C), 58.8, 109.7, 110.6, 111.6, 112.5, 113.2, 114.7,122.5, 125.0, 127.6, 127.8, 136.0, 138.4, 139.7, 144.9, 148.3, 148.9,149.4, 149.9. IR (KI3r) 3001, 2936, 2214, 1574, 1516 cm⁻¹. EIMS m/z (relint) 434 (100, M⁺); HREIMS m/z calcd for C₂₆H₃₀N₂O₄: 434.2206; found:434.2209 [M]⁺.

-   4. Synthesis of cycloadducts 12a-i and trans-13a-i by IADA

Typical procedure for the synthesis of cycloadducts 12a-i andtrans-13a-i by IADA. A 0.05 M solution of α-iminonitriles 14a-i (and15a-i, 5 mmol) in anhydrous toluene (10 mL) in a sealed tube was heatedat 160° C. for overnight. After cooling, the solvent was evaporated invacuo and the residue was purified by column chromatography over silicagel by eluting with a mixture of hexane/EtOAc (3:1 v/v), affordingcycloadducts 12a-i (and trans 13a-i). The complete spectral data ofcis-12i, trans-12a-i, and trans-13a-i are given below.

trans-7-(2,3,4-Trimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-hexahydroindolizine-5-carbonitrile(12a).

Yield 60%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.50-1.56 (1H, m), 1.60 (1H, td, J=12.2, 4.2Hz), 1.83-1.91 (1H, m), 1.91-1.95 (1H, m), 1.96 (1H, d, J=12.2 Hz),2.10-2.17 (1H, m), 3.23-3.31 (2H, m), 3.68-3.74 (1H, m), 3.79 (3H, s),3.82 (3H, s), 3.83 (3H, s), 3.84 (3H, s), 3.89 (3H, s), 4.39 (1H, d,J=4.2 Hz), 6.53 (1H, d, J=8.6 Hz), 6.69 (1H, d, J=8.6 Hz), 6.75 (1H, d,J=8.3 Hz), 6.90 (1H, d, J=2.0 Hz), 6.94 (1H, dd, J=8.3, 2.0 Hz); ¹³C NMR(125 MHz, CDCl₃): δ 24.3, 32.5, 34.5, 37.6, 50.6, 51.9, 55.8, 55.9(2×C), 60.7, 61.0, 106.5, 110.9, 111.5, 116.6, 117.8, 120.8, 124.0,125.5, 129.8, 131.4, 142.1, 148.3, 148.4, 151.0, 152.4. IR (KBr) 3015,2940, 2218, 1597, 1518 cm⁻¹. EIMS m/z (rel int) 450 (100, M⁺); HREIMSm/z calcd for C₂₆H₃₀N₂O₅: 450.2155; found: 450.2148 [M]⁺.

trans-6-(3,4-Dimethoxyphenyl)-7-(4-methoxyphenyl)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile (12b)

Yield 73%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.50-1.56 (1H, rn), 1.62 (1H, td, J=12.5, 4.0Hz), 1.81-1.97 (2H, in,), 1.99 (1H, d, J=12.5 Hz), 2.08-2.15 (1H, m),3.21-3.32 (2H, m), 3.69-3.74 (1H, m), 3.74 (3H, s), 3.81 (3H, s), 3.82(3H, s), 4.01 (1H, d, J=4.0 Hz), 6.74 (1H, d, J=8.2 Hz), 6.79 (2H, d,J=8.6 Hz), 6.90 (1H, d, J=2.1 Hz), 6.92 (1H, dd, J=8.2, 2.1 Hz), 7.06(2H, d, J=8.6 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.3, 32.5, 35.6, 43.4,50.6, 51.6, 55.2, 55.7, 55.9, 110.9, 111.6, 113.8 (2×C), 116.5, 117.4,120.8, 125.0, 129.2 (2×C), 131.3, 136.5, 148.2, 148.4, 158.1. IR (KBr)3001, 2932, 2214, 1601, 1512 cm⁻¹. EIMS m/z (rel int) 390 (26, M⁺), 295(100); HREIMS m/z calcd for C₂₄H₂₆N₂O₃: 390.1943; found: 390.1940 [M]⁺.

trans-6-(3,4-Dimethoxyplienyl)-7-(3-methoxyphenyl)-1,2,3,7,8,8a-hexahydroindolizine-5-earbonitrile(12c)

Yield 78%; yello)A^(,) syrup.

¹H NMR (500 MHZ, CDCl₃): δ 1.49-1.56 (1H, m), 1.64 (1H, td, J=12.4, 4.0Hz), 1.81-1.98 (2H, m), 2.04 (1H d, J=12.4 Hz), 2.08-2.16 (1H, m),3.23-3.32 (2H, 3.68-3.74 (1H, m), 3.76 (3H, s), 3.81 (3H, s), 3.82 (3H,s), 4.03 (1H, d, J=4.0 HZ), 6.68-6.71 (2H, m), 6.73-6.77 (2H, m),6.89-6.94 (2H, m), 7.17 (1H, t, J=8.0 Hz); ¹³C NMR (125 MHz, CDCl₃): δ24.3, 32.6, 35.3, 44.2, 50.6, 51.8, 55.2, 55.8, 55.9, 111.0, 111.3,111.8, 114.6, 116.5, 117.7, 120.7, 120.8, 124.4, 129.3, 131.4, 146.2,148.3, 148.5, 159.6. IR (KBr) 3001, 2924, 2218, 1593, 1516 cm⁻¹. EIMSm/z (rel int) 390 (100, M⁺); HREIMS m/z calcd for C₂₄H₂₆N₂O₃: 390.1943;found: 390.1937 [M]⁺.

trans-7-(3,4,5-Trimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile (12d)

Yield 67%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.50-1.60 (1H, m), 1.63 (1H, td, J=12.0, 5.2Hz), 1.84-1.99 (2H, m), 2.06 (1H, d, J=12.0 Hz), 2.13-2.20 (1H, m),3.24-3.31 (2H, m), 3.69-3.75 (1H, m), 3.78 (3H, s), 3.81 (6H, s), 3.83(6H, s), 4.00 (1H, d, J=5.2 Hz), 6.35 (2H, s), 6.78 (1H, d, J=8.3 Hz),6.91 (1H, d, J=2.1 Hz), 6.93 (1H, dd, J=8.3, 2.1 Hz); ¹³C NMR (125 MHz,CDCl₃): δ 24.3, 32.6, 35.6, 44.3, 50.6, 52.0, 55.8, 55.9, 56.2 (2×C),60.8, 105.5 (2×C), 111.0, 111.7, 116.5, 117.9, 120.9, 124.7, 131.4,136.5, 140.1, 148.4, 148.5, 153.0 (2×C). IR (KBr) 3019, 2938, 2220,1591, 1514 cm⁻¹. EIMS m/z (rel int) 450 (100, M⁺); HREIMS m/z calcd forC₂₆H₃₆N₂O₅; 450.2155; found: 450.2149 [M]⁺.

trans-6-(3,4,5-Trimethoxyphenyl)-7-(3,4-dimethoxyphenyl.)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile(12e)

Yield 62%; yellow syrup.

¹H NMR. (500 MHz, CDCl₃): δ 1.50-1.58 (1H, m), 1.61 (1H, td, J=12.5, 4.0Hz), 1.83-1.93 (1H, m), 1.93-2.00 (1H, m), 2.04 d, J 12.5 Hz), 2.10-2.18(1H, m), 3.23-3.35 (2H, m), 3.70-3.76 (1H, m), 3.78 (6H, s), 3.80 (3H,s), 3.83 (3H, s), 3.85 (3H, s), 3.99 (1H, d, J=4.0 Hz), 6.59 (2H, s),6.68-6.72 (2H, m), 6.77 (1H, d, J=7.9 Hz); ¹³C NMR (125 MHz, CDCl₃): δ24.3, 32.6, 35.4, 43.7, 50.6, 52.0, 55.9, 56.0, 56.1 (2×C), 60.8, 105.7(2×C), 111.1, 111.6, 116.4, 117.8, 120.5, 124.5, 134.2, 137.0, 137.4,147.7, 148.9, 152.8 (2×C). IR (KBr) 3005, 2940, 2220, 1587, 1506 cm⁻¹.EIMS m/z (rel int) 450 (100, M⁺) HREIMS m/z calcd for C₂₆H₃₀N₂O₅:450.2155; found; 450.2156 [M]⁺.

trans-7-(3,4-Dimethoxyphenyl)-6-(3-methoxyphenyl)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile(12f).

Yield 70%; yellow syrup.

¹H NMR. (500 MHz, CDCl₃): δ 1.51-1.58 (1H, m), 1.61 (1H, td, J=12.3, 4.0Hz), 1.82-1.99 (2H, m), 2.03 (1H, d, J=12.3 Hz), 2.10-2.17 (1H, m),3.21-3.28 (1H, 3.30 (1H, td, J=10.0, 6.3 Hz), 3.70-3.75 (1H, m), 3.75(3H, s), 3.80 (3H, s), 3.83 (3H, s), 4.04 (1H, d, J=4.0 Hz), 6.66 (1H,s), 6.67 (1H, d, J=8.1 Hz), 6.72 (1H, d, J=8.1 Hz), 6.74 (1H, d, J=8.1Hz), 6.91 (1H, s), 6.97 (1H, d, J=8.1 Hz), 7.16 (1H, t, J=8.1 Hz); ¹³CNMR (125 MHz, CDCl₃): δ 24.2, 32.5, 35.5, 43.6, 50.5, 51.9, 55.1, 55.8,55.9, 111.0, 111.6, 112.5, 114.1, 116.1, 118.1, 120.4, 120.8, 124.5,129.1, 136.8, 140.1, 147.6, 148.8, 159.3. IR (KBr) 3066, 2935, 2218,1612, 1566, 1513 cm⁻¹. EIMS m/z (rel int) 390 (100, M⁺); HREIMS m/zcalcd for C₂₄H₂₆N₂O₃: 390.1943; found: 390.1941 [M]⁺.

trans-743,4-Dimethoxyphenyl)-644-methoxyphenyl)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile(12g).

Yield 64%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): b 1.50-1.56 (1H, m), 1.62 (1H, td, J=12.4, 4.0Hz), 1.82-1.98 (2H, in,), 2.02 (1H, d, J=12.4 Hz), 2.10-2.17 (1H, m),3.21-3.30 (2H,) 3.70 (1H, td, J=9.3, 2.0 Hz), 3.75 (3H, s), 3.80 (3H,s), 3.83 (3H, s), 4.00 (1H, d, J=4.0 Hz), 6.64 (1H, d, J=1.9 Hz), 6.66(1H, dd, J=8.1, 1.9 Hz), 6.74 (1H, d, J=8.1 Hz), 6.79 (2H, d, J=8.8 Hz),7.29 (2H, d, J=8.8 Hz); ¹³C NMR (125 MHz, CDC13): δ 24.3, 32.5, 35.7,43.8, 50.5, 51.7, 55.1, 55.8, 55.9, 111.0, 111.7, 113.7 (2×C), 116.5,117.6, 120.4, 125.2, 129.4 (2×C), 131.1, 136.9, 147.5, 148.8, 158.8. IR(KBr) 3005, 2943, 2218, 1601, 1570, 1512 cm⁻¹. EIMS m/z (rel int) 390(100, M⁺); HREIMS m/z calcd for C₂₄H₂₆N₂O₃: 390.1943; found: 390.1947[M]⁺.

trans-7-(3,4-Trimethoxyphenyl)-7-(3,4-dimethoxyphenyI)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile(12 h).

Yield 78%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.52-1.57 (1H, m), 1.63 (1H, td, J=12.7, 4.5Hz), 1.82-1.96 (2H, m), 1.98 OK d, J=12.7 Hz), 2.10-2.18 (1H, m),3.23-3.33 (2H, ), 3.69 (1H, td, J=9.0, 1.9 Hz), 3.79 (3H, s), 3.81 (3H,s), 3.83 (3H, s), 3.84 (3H, s), 3.89 (3H, s), 4.11 (1H, d, J=4.5 Hz),6.55 (1H, d, J=8.6 Hz), 6.66-6.70 (2H, m), 6.75 (1H, d, J=8.0 Hz), 6.88(1H, d, J=8.6 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.3, 32.6, 35.5, 43.3,50.7, 51.7, 55.7, 55.8, 55.9, 60.8, 61.2, 1069, 110.9, 111.9, 115.9,119.3, 120.4, 123.2, 125.4, 126.3, 137.0, 142.1, 147.5, 148.7, 151.8,153.4. IR (KBr) 3021, 2941, 2222, 1595, 1514 cm⁻¹. EIMS m/z (rel int)450 (88, M⁺), 419 (100); HREIMS m/z calcd for C₂₆H₃₀N₂O₅: 450.2155;found: 450.2157 [M]⁺.

trans-6,7-Bis(3,4-dimethoxyphenyI)-1,2,3,7,8,8a-hexahydroindolizine-5-carbonitrile(trans-121).

Yield 64%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.50-1.57 (1H, m), 1.63 (1H, td, J=12.0, 4.0Hz), 1.82-1.99 (2H, m,), 2.03 (1H, d, J=12.0 Hz), 2.10-2.17 (1H, m),3.22-3.32 (2H, m), 3.68-3.75 (1H, m), 3.81 (3H, s), 3.82 (3H, s), 3.83(3H, s), 3.84 (3H, s), 4.01 (1H, d, J=4.0 Hz), 6.65-6.70 (2H, m),6.73-6.78 (2H, m), 6.89-6.96 (2H, m); ¹³C NMR (125 MHz, CDCl₃): δ 24.2,32.5, 35.5, 43.7, 50.5, 51.8, 55.8 (4×C), 110.9, 111.0, 111.6 (2×C),116.5, 117.5, 120.4, 120.8, 124.9, 131.3, 136.9, 147.5, 148.2, 148.4,148.8. IR (KBr) 3075, 2909, 2218, 1597, 1512 cm ⁻¹. EIMS m/z (rel int)420 (100, M⁺); HREIMS m/z calcd for C2.5H28N201: 420.2049; found:420.2054 [M]^(T).

trans-2-(2,3,4-Trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13a)

Yield 84%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.27-1.36 (2H, m), 1.50-1.66 (2H, m),1.71-1.82 (3H, m), 2.02 (1H, td, J=12.2, 5.0 Hz), 2.61 (1H, t, J=12.2Hz), 2.70 (1H, td, J=12.0, 2.3 Hz), 3.77 (3H, s), 3.81 (3H, s), 3.83(3H, s), 3.84 (3H, s), 3.85 (3H, s), 3.98 (1H, d, J=12.0 Hz), 4.17 (1H,d, J=5.0 Hz), 6.62 (1H, d, J=8.8 Hz), 6.73 (1H, d, J=8.3 Hz), 6.80 (1H,d, J=1.9 Hz), 6.81 (1H, d, J=8.8 Hz), 6.86 (1H, dd, J=8.3, 1.9 Hz); ¹³CNMR (125 MHz, CDCl₃): δ 24.1, 25.9, 31.9, 36.2, 37.0, 50.9, 51.6, 55.7,55.8, 55.9, 60.6, 60.9, 106.4, 110.7, 111.7, 116.1, 121.0, 121.3, 123.9,127.9, 130.3, 131.9, 142.1, 148.3, 148.4, 151.0, 152.5. IR (KBr) 3057,2943, 2218, 1600, 1516 cm⁻¹. EIMS m/z rel int) 464 (100, M⁺); HREIMS m/zcalcd for C₂₇H₃₂N₂O₅: 464.2311; found: 464.2308 [M]⁺.

trans-3-(3,4-Dimethoxyphenyl)-2-(4-methoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13b)

Yield 90%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.26-1.35 (2H,), 1.49-1.64 (2H, m), 1.71-1.82(3H, m), 2.07 (1H, td, J=12.5, 5.4 Hz), 2.63 (1H, t, J=12.5 Hz), 2.71(1H, t, J=11.5 Hz), 3.75 (3H, s), 3.78 (3H, s), 3.80 (1H, d, J=5.4 Hz),3.81 (3H, s), 3.98 (1H, d, J=11.5 Hz), 6.72 (1H, d, J=8.3 Hz), 6.78(11-1:, s), 6.83 (114, d, J 8.3 Hz), 6.85 (2H, d, J 8.1 Hz), 7.12 (2H,d, J=8.1 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.1, 26.0, 32.0, 37.6, 43.0,50.9, 51.3, 55.2, 55.7, 55.8, 110.8, 111.9, 113.8 (2×C), 116.0, 120.9,121.0, 127.6, 129.3 (2×C), 131.9, 137.0, 148.3, 148.5, 158.3. IR (KBr)3001, 2936, 2218, 1601, 1582, 1512 cm⁻¹. EIMS m/z (rel int) 404 (100,M⁺); HREIMS m/z calcd for C₂₅H₂₈N₂O₃: 404.2100; found: 404.2102 [M]⁺.

trans-3-(3,4-Dimethoxyphenyl)-2-(3-methoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13c)

Yield 91%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.26-1.35 (2H, m), 1.51-1.65 (2H, m),1.71-1.81 (2H, m), 1.83 (1H, d, J=13.2 Hz), 2.09 (1H, td, J=12.2, 5.7Hz), 2.66 (1H, t, J=12.2 Hz), 2.72 (1H, td, J=12.2, 2.3 Hz), 3.76 (3H,s), 3.79 (1H, br s), 3.81 (3H, s), 3.82 (1H, d, J=5.7 Hz), 3.99 (1H, d,J=12.2 Hz), 6.73 (1H, d, J=8.4 Hz), 6.74-6.77 (2H, m), 6.79 (1H, d,J=2.0 Hz), 6.81 (1H, d, J=8.4 Hz), 6.84 (1H, dd, J=8.4, 2.0 Hz), 7.23(1H, t, J=8.4 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.0, 25.9, 32.0, 37.3,43.8, 50.9, 51.5, 55.2, 55.7, 55.8, 110.8, 111.5, 111.9, 114.7, 116.0,120.8, 121.1, 121.2, 127.0, 129.4, 131.8, 146.6, 148.3, 148.5, 159.6. IR(KBr) 3055, 2920, 2214, 1643, 1570, 1504 cm⁻¹. EIMS m/z (rel int) 404(100, M⁺); HREIMS m/z calcd for C₂₅H₂₈N₂O₃: 404.2100; found: 404.2107[M]⁺.

trans-2-(3,4,5-Trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinalizine-4-carbonitrile(13d)

Yield 90%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): (δ 1.26-1.39 (2H,), 1.57-1.67 (2H, rn),1.72-1.87 (3H, m), 2.08 (1H, td, J=12.5, 5.6 Hz), 2.62-2.71 (2H, m),3.78 (3H, s), 3.79 (1H, d, J=5.6 Hz), 3.82 (6H, s), 3.83 (6H, s), 4.01(1H, d, J=11.4 Hz), 6.42 (2H, s), 6.75 (1H, d, J=8.2 Hz), 6.82 (1H, d,J=1.4 Hz), 6.85 (1H, dd, J=8.2, 1.4 Hz); ¹³C NMR (125 MHz, CDCl₃): δ24.0, 25.9, 31.8, 37.3, 43.9, 51.0, 51.7, 55.7, 55.8, 56.1 (2×C), 60.8,105.5 (2×C) 110.8, 111.8, 115.9, 121.1 (2×C) 127.1, 131.8, 136.6, 140.4,148.3, 148.5, 153.1 (2×C). IR (KBr) 3005, 2938, 2220, 1589, 1516, 1504cm⁻¹. EIMS m/z (rel int) 464 (77, M⁺), 269 (100); HREIMS m/z calcd forC₂₇H₃₂N₂O₅: 464.2311; found: 464.2306 [M]⁺.

trans-3-(3,4,5-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13e).

Yield 86%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.27-1.38 (2H, m), L57-1.65 (2H,), 1.74-L85(3H, m), 2.06 (1H, td, J=12.9, 5.3 Hz), 2.67 (1H, td, J=12.9, 2.0 Hz),2.70 (1H, td, J=12.2, 2.4 Hz), 3.72 (6H, s), 3.77 (1H, d, J=5.3 Hz),3.80 (3H, s), 3.86 (3H, s), 3.87 (3H, s), 4.02 (1H, d, =12.2 Hz), 6.49(2H, s), 6.73 (1H, J=1.8 Hz), 6.77 (1H, dd, J=8.2, 1.8 Hz), 6.84 (1H, d,J=8.2 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.1, 26.0, 32.0, 37.4, 43.4,50.8, 51.6, 55.9 (2×C), 56.0 (2×C), 60.8, 105.9 (2×C), 111.1, 111.7,115.8, 120.5, 121.0, 127.1, 134.7, 137.5, 137.6, 147.8, 148.9, 152.7(2×C). IR (KBr) 3005, 2938, 2218, 1576, 1510 cm⁻¹. EIMS m/z (rel int)464 (100, M⁺); m/z calcd for C₂₇H₃₂N₂O₅; 464.2311; found: 464.2306 [M]⁺.

trans-2-(3,4-Dimethoxyphenyl)-3-(3-methoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13f)

Yield 90%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.27-1.37 (2H, m), 1.53-1.65 (2H, m),1.71-1.85 (3H, m), 2.06 (1H, td, J=12.0, 4.5 Hz), 2.65 (1H, t, J=12.0Hz), 2.70 (1H, td, J=12.0, 2.2 Hz), 3.72 (3H, s), 3.81 (1H, d, J=4.5Hz), 3.84 (3H, s), 3.85 (3H, s), 4.00 (1H, d, J=12.0 Hz), 6.70 (1H, s),6.72-6.76 (2H, m), 6.81 (1H, d, J=8.0 Hz) 6.82 (1H, s), 6.87 (1H, d,J=7.7 Hz), 7.15 (1H, t, J=8.0 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.1,25.9, 31.9, 37.6, 43.2, 50.9, 51.6, 55.1, 55.9 (2×C), 111.1, 111.8,113.0, 114.3, 115.7, 120.5, 121.0, 121.4, 127.2, 129.1, 137.3, 140.7,147.8, 148.9, 159.2. IR (KBr) 3017, 2935, 2218, 1612, 1516 cm⁻¹. EIMSm/z (rel int) 404 (100, M⁺); HREIMS m/z calcd for C₂₅H₂₈N₂O₃: 404.2100;found: 404.2102 [M]⁺.

trans-2-(3,4-Dimethoxyphenyl)-3-(4-methoxyphenyl)-2,6,7,8,9,9a-hexahydro-quinolizine-4-carbonitrile(13g)

Yield 92%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.26-1.35 (2H, m), 1.50-1.64 (2H, m),1.70-1.84 (3H, m), 2.07 (1.H, t, J=11.0 Hz), 2.62 (1H, t, J=11.0 Hz),2.68 (1H, t, J=12.2 Hz), 3.74 (3H, s), 3.80 (1H, hr s), 3.85 (6H, s),3.98 (1H, d, J=12.2 Hz), 6.69 (1H, s), 6.73 (1H, d, J=8.2 Hz), 6.77 (2H,d, J=8.2 Hz), 6.81 (d, J 8.2 Hz), 7.21 (2H, d, J=8.2 Hz); ¹³C NMR (125MHz, CDCl₃): δ 24.1, 25.9, 31.9, 37.6, 43.3, 51.0, 51.5, 55.1, 55.8(2×C), 111.0, 111.7, 113.6 (2×C), 116.0, 120.5, 121.0, 127.6,129.6(2×C), 131.6,137.3, 147.7, 148.8, 159.0. IR (KBr) 3005, 2940, 2218,1605, 1512 cm⁻¹. EIMS m/z (rel int) 404 (100, M⁺); HREIMS m/z calcd forC₂₅H₂₈N₂O₃: 404.2100; found: 404.2097[M]⁺.

trans-3-(2,3,4-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13h)

Yield 93%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.28-1.39 (2H, m), 1.50-1.63 (2H, m),1.69-1.76 (1H, m), 1.76-1.85 (2H, m), 2.10 (1H, td, J=12.0, 5.6 Hz),2.62-2.75 (2H, m), 3.78 (3H, s), 3.83 (6H, s), 3.84 (3H, s), 3.90 (3H,s), 3.90-3.95 (2H, m), 6.51 (1H, d, J=8.6 Hz), 6.69 (1H, s), 6.72 (1H,d, J=8.2 Hz), 6.77 (1H, d, J=8.6 Hz), 6.78 (1H, d, J=8.2 Hz); ¹³C NMR(125 MHz, CDCl₃): δ 24.2, 25.8, 31.8, 37.6, 42.7, 51.2, 51.7, 55.8(3×C), 60.9, 61.4, 106.9, 110.8, 112.0, 115.5, 120.5 (2×C), 122.8,125.8, 126.1, 137.2, 142.2, 147.6, 148.7, 152.0, 153.6. IR (KBr) 3019,2938, 2224, 1595, 1518 cm⁻¹. EIMS m/z (rel int) 464 (96,M⁺), 433 (100);HREIMS m/z calcd for C₂₇H₃₂N₂O₅: 464.2311; found: 464.2321 [M]⁺.

trans-2,3-Bis(3,4-dimethoxyphenyl)-2,6,7,8,9,9a-hexahydro-1H-quinolizine-4-carbonitrile(13i).

Yield 92%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.27-1.37 (2H, m), 1.51-1.64 (2H, m),1.72-1.86 (3H, m), 2.07 (1H, td, J=13.0, 5.3 Hz), 2.62-2.73 (2H, m),3.76 (3H, s), 3.80 (1H, d, J=5.3 Hz), 3.81 (3H, s), 3.85 (6H, s), 4.00(1H, d, J=11.9 Hz), 6.71-6.77 (3H, m), 6.80-6.86 (3H, m); ¹³C NMR (125MHz, CDCl₃); δ 24.1, 26.0, 31.9, 37.5, 43.4, 50.9, 51.6, 55.8 (4×C),110.8, 111.0, 111.7, 111.9, 116.0, 120.5, 120.9, 121.0, 127.4, 131.9,137.4, 147.7, 148.3, 148.5, 148.9. IR (KBr) 3009, 2932, 2218, 1601, 1512cm⁻¹. EIMS m/z (rel int) 434 (100, M⁺); HREIMS m/z calcd for C₂₆H₃₀N₂O₄:434.2206; found 434.2204 [M]⁺.

-   5. Synthesis of Compounds 10a-i and 11a-i by Reductive Decyanization

Typical procedure for the synthesis of cis-stilbene derivatives 10a-i(and 11a-i) by reductive decyanization. A mixture of cycloadducts 12a-i(and trans-13a-i, 0.25 mmol) and NaBH₄ (5 mmol) in 2-propanol (5 mL) ina sealed tube was heated at 100° C. (or 120° C.) for 24 h. Aftercooling, the reaction mixture was quenched with H₂O (1 mL), and thesolvent was evaporated in vacua. The residue was diluted with H₂O (10mL) and extracted with CHCl₃ (5×20 mL), and the combined extracts werewashed with H₂O, dried over anhydrous MgSO₄, and filtered. The filtratewas concentrated and the residue was purified by column chromatographyover silica gel by eluting with EtOAc, affording pure stilbenederivatives 10a-i (and 11a-i). The complete spectral data of thesecompounds are given below.

7-(2,3,4-Trimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-1,23,5,8,8a-hexahydroindolizine(10a)

Yield 92%; pale yellow syrup.

¹H NMR (500 MHz, CDCl3): δ 1.48-1.58 (1H, m), 1.77-1.87 (1H, m),1.89-2.00 (1H, m), 2.03-2.12 (1H, m), 2.26 (1H, q, J=8.5 Hz), 2.30-2.49(2H, m), 2.69 (1H, d, J=9.8 Hz), 3.14 (1H, d, J=15.8 Hz), 3.32 (1H, t, J8.5 Hz), 3.61 (3H, s), 3.77 (3H, s), 3.78 (3H, s), 3.79 (3H, s), 3.86(3H, s), 3.90 (1H, d, J=15.8 Hz), 6.39 (1H, d, J=8.6 Hz), 6.52 (1H, d,J=8.6 Hz), 6.55 (1H, d, J=1.5 Hz), 6.66 (1H, d, J=8.3 Hz), 6.70 (1H, dd,J=8.3, 1.5 Hz); ¹³ C NMR (125 MHz, CDCl₃): δ 21.5, 303, 38.5, 54.4,55.5, 55.7, 55.8, 57.5, 60.2, 60.6, 60.7, 106.8, 110.4, 112.7, 120.4,125.3, 129.1, 131.2, 133.3, 133.6, 141.9, 147.3, 147.9, 151.5, 152.4. IR(KBr) 3013, 2930, 1601, 1514 cn⁻¹. EIMS m/z (rel int) 425 (40, M⁺), 356(100); HREIMS m/z calcd for C₂₅H₃₁NO₅: 425.2202; found: 425.2210 [M]⁺.

Hispidine (10b)

Yield 100%; white powder, mp 87-90° C.

¹H NMR (500 MHz, CDCl₃): δ 1.50-1.60 (1H, m), 1.78-1.88 (1H, m),1.89-2.00 (1H, m), 2.05-2.14 (1H, m), 2.25 (1H, q, J=8.9 Hz), 2.36-2.45(2H, m), 2.71 (1H, dd, J=12.9, 2.1 Hz), 3.08 (1H, d, J=15.8 Hz), 3.31(1H, td, J=8.9, 1.8 Hz), 3.57 (3H, s), 3.72 (3H, s), 3.81 (3H, s), 3.89(1H, d, J=15.8 Hz), 6.48 (1H, s), 6.64-6.69 (4H, m), 6.95 (2H, d, J=8.7Hz); ¹³C NMR (125 MHz, CDCl₃): δ 21.5, 30.8, 38.8, 54.3, 55.1, 55.5,55.7, 57.7, 60.4, 110.5, 113.3 (3×C), 120.9, 129.9 (2×C), 132.5, 132.7,133.6, 135.0, 147.3, 148.1, 157.8. IR (KBr) 3121, 2916, 1605, 1574, 1516cm⁻¹. EIMS m/z (rel int) 365 (30, M⁺), 265 (100); HREIMS m/z calcd forC₂₃H₂₇NO₃: 365.1991; found: 365.1996 [M]⁺.

6-(3,4-Dimethoxyphenyl)-7-(3-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine(10c).

Yield 96%; white powder, rip 119-120° C.

¹H NMR (500 MHz, CDCl₃): δ 1.50-1.60 (1H,), 1.78-1.88 (1H, m), 1.90-2.00(1H, m), 2.06-2.14 (1H, m), 2.26 (1H, q, J=9.0 Hz), 2.37-2.47 (2H, m),2.72 (1H, dd, J=13.0, 2.2 Hz), 3.09 (1H, d, J=16.0 Hz), 3.32 (1H, td,J=9.0, 2.0 Hz), 3.55 (3H, s), 3.60 (3H, s), 3.80 (3H, s), 3.89 (1H, d,J=16.0 Hz), 6.49 (1H, s), 6.57 (1H, t, J=2.0 Hz), 6.61-6.68 (4H, m),7.05 (1H, t, J=7.9 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 21.5, 30.8, 38.8,54.3, 55.0, 55.6, 55.7, 57.6, 60.3, 110.5, 111.9, 113.2, 114.5, 120.8,121.3, 128.8, 133.2, 133.3, 133.4, 144.2, 147.5, 148.1, 159.1. IR (KBr)3063, 2928, 1597, 1578, 1516 cm⁻¹. EIMS m/z (rel int) 365 (17, M⁺), 265(100); HREIMS m/z calcd for C₂₃H₂₇NO₃: 365.1991; found: 265.200 [M]⁺.

7-(3,4,5-Trimethoxyphenyl)-6-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexa.hydroindolizine(10d)

Yield 96%; pale yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.52-1.62 (1H, m), 1.81-1.89 (1H, m),1.91-2.01 (1H, m), 2.08-2.16 (1H, m), 2.27 (1H, q, J=8.8 Hz), 2.37-2.47(2H, m), 2.74 (1H, d, J=13.0 Hz), 3.10 (1H, d, J=16.1 Hz), 3.32 (1H, t,J=8.8 Hz), 3.59 (3H, s), 3.62 (6H, s), 3.77 (3H, s), 3.81 (3H, s), 3.89(1H, d, J=16.1 Hz), 6.27 (2H, s), 6.53 (1H, d, J=1.4 Hz), 6.67 (1H, dd,J=8.3, 1.4 Hz), 6.70 (1H, d, J=8.3 Hz); ¹³C NMR (125 MHz, CDCl₃): δ21.5, 30.8, 38.6, 54.3, 55.7, 55.8, 55.9 (2×C), 57.6, 60.4, 60.8, 106.3(2×C), 110.7, 113.0, 120.8, 133.1, 133.2, 133.6, 136.4, 138.1, 147.6,148.3, 152.6 (2×C). IR (KBr) 3019, 2911, 1582, 1514 cm⁻¹. EIMS m/z (relint) 425 (48, M⁺), 325 (100); HREIMS m/z calcd for C₂₅H₃₁NO₅; 425.2202;found: 425.2209 [M]⁺.

6-(3,4,5-Timethoxyphenyl)-7-(3,4-dimethoxyphenyel)-1,2,3,5,8,8a-hexahydroindolizine(10e)

Yield 100%; pale yellow syrup,

¹H NMR (500 MHz, CDCl₃): δ 1.51-1.62 (1H, m), 1.79-1.90 (1H, m),1.90-2.01 (1H, m), 2.07-2.16 (1H, m), 2.27 (1H, q, J=8.8 Hz), 2.38-2.48(2H, m), 2.75 (1H, d, J=13.0 Hz), 3.11 (1H, d, J=16.0 Hz), 3.32 (1H, t,J=8.8 Hz), 3.57 (3H, s), 3.63 (6H, s), 3.78 (3H, s), 3.81 (3H, s), 3.88(1H, d, J=16.0 Hz), 6.29 (2H, s), 6.52 (1H, s), 6.66-6.72 (2H, m); ¹³CNMR (125 MHz, CDCl₃): δ 21.5, 30.9, 38.5, 54.2, 55.6, 55.8, 56.0 (2×C),57.6, 60.4, 60.8, 106.5 (2×C), 110.6, 112.8, 120.5, 133.0, 133.2, 135.0,136.5, 136.7, 147.4, 148.1, 152.7 (2×C). IR (KBr) 3018, 2934, 1582, 1516cm⁻¹. EIMS m/z (rel int) 425 (44, M⁺) 325 (100); HREIMS m/z calcd forC₂₅H₃₁NO₅: 425.2202; found: 425.2209 [M]⁺.

7-(3,4-Dimethoxyphenyl)-6-(3-methoxyphenyl)-1,2,3,5,8,8a-hexahydroindolizine(10f)

Yield 100%; white powder, mp 53-55° C.

¹H NMR (500 MHz, CDCl₃): δ 1.52-1.62 (1H, m), 1.78-1.88 (1H, m),1.90-2.00 (1H, m), 2.06-2.15 (1H, m), 2.25 (1H, q, J=8.9 Hz), 2.37-2.48(2H, m), 2.73 (1H, dd, J=13.0, 2.2 Hz), 3.10 (1H, d, J=16.0 Hz), 3.30(1H, td, J=8.9, 1.9 Hz), 3.53 (3H, s), 3.61 (3H, s), 3.80 (3H, s), 3.87(1H, d, J=16.0 Hz), 6.48 (1H, s), 6.59 (1H, t, J=1.8 Hz), 6.62-6.71 (4H,m), 7.06 (1H, t, J=7.9 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 21.5, 30.8,38.5, 54.3, 55.1, 55.5, 55.7, 57.8, 60.4, 110.5, 112.1, 113.0, 114.8,120.5, 121.5, 128.9, 133.1, 133.2, 134.9, 142.8, 147.3, 147.9, 159.2. IR(KBr) 3067, 2916, 1582, 1516 cm⁻¹. EIMS m/z (rel int) 365 (100, M⁺);HREIMS m/z calcd for C₂₃H₂₇NO₃: 365.1991; found: 365.1996 [M]⁺.

Seco-antofine (10g).

Yield 100%; white powder, mp 108-109° C.

¹H NMR (500 MHz, CDCl₃): δ 1.51-1.61 (1H, m), 1.78-1.88 (1H, m),1.89-2.00 (1H, m), 2.06-2.14 (1H, m), 2.25 (1H, q, J=8.8 Hz), 2.36-2.46(2H, 2.73 (1H, dd, J=12.9, 2.1 Hz), 3.07 (1H, d, J=15.9 Hz), 3.30 (1H,td, J=8.8, 1.9 Hz), 3.54 (3H, s), 3.72 (3H, s), 3.80 (3H, s), 3.86 (1H,d, J=15.9 Hz), 6.47 (1H, d, J=1.2 Hz), 6.65-6.68 (2H, m), 6.68 (2H, d,J=8.8 Hz), 6.97 (2H, d, J=8.8 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 21.5,30.8, 38.5, 54.3, 55.1, 55.5, 55.7, 57.9, 60.4, 110.5, 113.1, 113.4(2×C), 120.7, 130.2 (2×C), 132.6, 132.7, 133.6, 135.1, 147.2, 147.9,158.0. IR (KBr) 3062, 2967, 1643, 1605, 1582, 1574, 1520 cm⁻¹. EIMS m/z(rel int) 365 (46, M⁺), 265 (100); HREIMS m/z calcd for C₂₃H₂₇NO₃;365.1991; found: 365.1992 [M]⁺

6-(2,3,4-Trimethoxyphenyl)-7-(3,4-dimethoxyphenyl)-1,2,3,5,8,8a-hexa.hydroindolizine(10h).

Yield 94%; pale yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.54-1.63 (1H, m), 1.78-1.86 (1H, m),1.90-2.00 (1H, m), 2.05-2.13 (1H, m), 2.23 (1H, q, J=9.0 Hz), 2.40-2.53(2H, m), 2.69 (1H, d, J=15.9 Hz), 3.11 (1H, br d, J=14.6 Hz), 3.27 (1H,td, J=9.0, 1.7 Hz), 3.58 (3H, s), 3.74 (1H br d, J=14.6 Hz), 3.77 (3H,s), 3.78 (3H, s), 3.79 (3H, s), 3.82 (3H, s), 6.43 (1H, d, J=8.6 Hz),6.53 (1H, d, J=1.7 Hz), 6.58 (1H d, J=8.6 Hz), 6.66 (1H, d, J=8.3 Hz),6.70 (1H, dd, J=8.3, 1.7 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 21.4, 30.7,38.2, 54.3, 55.5, 55.7, 55.8, 57.8, 60.5, 60.6, 60.7, 106.9, 110.3,112.4, 120.1, 125.7, 127.7, 130.5, 133.3, 135.1, 141.9, 147.1, 147.7,151.6, 152.5. IR (KBr) 3021, 2940, 1599, 1518 cm⁻¹. EIMS m/z (rel int)425 (100, M⁺); HREIMS m/z calcd for C₂₅H₃₁NO₅: 425.2202; found: 425.2191[M]⁺.

Septicine (10i)

Yield 100%; white powder, mp 142-144° C. (X. Xu, Y Liu, C. M. Park,Angew Chem. Int. Ed. 2012, 51, 9372-9376; mp 134-135° C.).

¹H NMR (500 MHz, CDCl₃): δ 1.51-1.61 (1H, m), 1.78-1.88 (1H, m),1.90-2.00 (1H, m), 2.06-2.15 (1H, m), 2.26 (1H, q, J=8.9 Hz), 2.36-2.46(2H, m), 2.74 (1H, dd, J=12.9, 2.1 Hz), 3.09 (1H, d, J=15.8 Hz), 3.31(1H, td, J=8.9, 1.8 Hz), 3.57 (3H, s), 3.60 (3H, s), 3.80 (3H, s), 3.81(3H, s), 3.89 (1H, d, J=15.8 Hz), 6.52 (1H, d, J=1.7 Hz), 6.54 (1H, d,J=1.8 Hz), 6.63-6.69 (4H, m); ¹³C NMR (125 MHz, CDCl₃): δ 21.5, 30.9,38.7, 54.3, 55.6, 55.7, 55.8 (2×C), 57.7, 60.4, 110.6, 110.7, 112.9,113.1, 120.7, 121.0, 132.8, 132.9, 133.8, 135.2, 147.3, 147.5, 148.1,148.2. IR (KBr) 3044, 2924, 1597, 1532, 1516, 1508 cm⁻¹. ELMS m/z (relint) 395 (59, M⁺), 295 (100); HREIMS m/z calcd for C₂₄H₂₉N₄: 395.2097;found: 395.2090 [M]⁺.

2-(2,3,4-Trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine(11a)

Yield 95%; pale yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.27-1.42 (2H, m), 1.69-1.77 (2H, m),1.77-1.85 (2H, m), 2.09-2.16 (1H, m), 2.27-2.37 (2H, m), 2.50 1H, br d,J=12.9 Hz), 3.06-3.14 (2H, m), 3.57 (3H, s), 3.65 (1H, d, J=16.5 Hz),3.76 (3H, s), 3.78 (3H, s), 3.79 (3H, s), 3.86 (3H, s), 6.39 (1H, d,J=8.5 Hz), 6.51 (1H, d, J=8.5 Hz), 6.55 (1H, d, J=1.8 Hz), 6.66 (1H, d,J=8.3 Hz), 6.70 (1H, dd, J=8.3, 1.8 Hz); ¹³C NMR (125 MHz, CDCl₃): δ24.4, 25.9, 33.2, 39.6, 55.5, 55.6, 55.7, 55.8, 57.8, 59.8, 60.7 (2×C),106.8, 110.3, 112.6, 120.3, 125.3, 128.6, 130.1, 132.1, 133.2, 141.9,147.3, 147.9, 151.5, 152.4. IR (KBr) 3057, 2930, 1595, 1514 cm⁻¹. EIMSm/z (rel int) 439 (57, M⁺), 356 (100); HREIMS m/z calcd for C₂₆H₃₃NO₅:439.2359; found: 439.2354 [M]⁺.

3-(3,4-Dimethoxyphenyl)-2-(4-methoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine(11b)

Yield 100%; white powder, mp 106-108° C.

¹H NMR (500 MHz, CDCl₃): δ 1.27-1.43 (2H, m), 1.63-1.73 (2H, m),1.77-1.89 (2H, m), 2.12 (1H, t, J=11.2 Hz), 2.25-2.34 (1H, m), 2.39 (1H,dd, J=17.2, 10.5 Hz), 2.51 (1H, d, J=17.2 Hz), 3.00-3.15 (2H, m), 3.57(3H, s), 3.63 (1H, d, J=16.3 Hz), 3.72 (3H, s), 3.81 (3H, s), 6.49 (1H,s), 6.63-6.71 (4H, m), 6.95 (2H, d, J=8.4 Hz); ¹³C NMR (125 MHz, CDCl₃):δ 24.4, 25.9, 33.3, 39.8, 55.1, 55.5, 55.6, 55.7, 57.9, 60.1, 110.5,113.2, 113.3 (2×C), 120.9, 129.8 (2×C), 131.3, 131.4, 133.3, 134.4,147.4, 148.1, 157.8. IR (KBr) 3009, 2920, 1605, 1574, 1512 cm⁻¹. EIMSm/z (rel int) 379 (38, M⁺), 265 (100); HREIMS m/z ceded for C₂₄H₂₉NO₃:379.2147; found: 379.2155 [M]⁺.

3-(3,4-Dimethoxyphenyl)-2-(3-methoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine(11e)

Yield 97%; white powder, mp 138-139° C.

¹H NMR (500 MHz, CDCl₃): δ 1.28-1.43 (2H, m), 1.59-1.78 (2H, m),1.78-1.90 (2H, m), 2.12 (1H, td, J=11.3, 5.0 Hz), 2.26-2.36 (1H, m),2.41 (1H, dd, J=17.4, 11.9 Hz), 2.52 (1H, d, J=17.4 Hz), 3.03-3.14 (2H,m), 3.55 (3H, s), 3.60 (3H, s), 3.63 (1H, d, J=16.5 Hz), 3.80 (3H, s),6.50 (1H, s), 6.57 (1H, t, J=1.5 Hz), 6.60-6.71 (4H, m), 7.05 (1H, t,J=7.4 Hz); ¹³ C NMR (125 MHz, CDCl₃): δ 24.4, 25.9, 33.3, 39.8, 55.0,55.5, 55.6, 55.7, 57.9, 60.0, 110.6, 111.9, 113.1, 114.4, 120.7, 121.2,128.8, 131.9, 132.0, 133.1, 143.6, 147.5, 148.1. 159.1. IR (KBr) 3060,2920, 1605, 1574, 1512 cm⁻¹. EIMS m/z (rel int) 379 (28, 296 (100);HREIMS m/z calcd for C₂₄H₂₉NO₃: 379.2147; found: 379.2144 [M]⁺.

2-(3,4,5-Trimethoxyphenyl)-3-(3,4-dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine (11d)

Yield 98%; pale yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.32-1.41 (2H, m), 1.67-1.74 (1H, m),1.78-1.95 (3H, m), 2.12 (1H, td, J=11.2, 4.4 Hz), 2.27-2.35 (1H, m),2.41 (1H, dd, J=17.3, 9.1 Hz), 2.53 (1H, d, J=17.3 Hz), 3.03-3.13 (2H,m), 3.59 (3H, s), 3.61 (6H, s), 3.63 (1H, d, J=16.5 Hz), 3.77 (3H, s),3.81 (3H, s), 6.27 (2H, s), 6.54 (1H, s), 6.66-6.72 (2H, m); ¹³C NMR(125 MHz, CDCl₃): δ 24.3, 25.9, 33.3, 39.5, 55.6, 55.7, 55.8, 55.9(2×C), 57.9, 60.1, 60.8, 106.2 (2×C), 110.7, 112.9, 120.8, 131.8, 132.0,133.2, 136.4, 137.5, 147.6, 148.3, 152.6 (2×C). IR (KBr) 3019, 2936,1582, 1514 cm⁻¹. EIMS m/z (rel int) 439 (63, M⁺), 325 (100); HREIMS m/zcalcd for C₂₆H₃₃NO₅: 439.2359; found: 439.2351 [M]⁺.

3-(3,4,5-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine(11e)

Yield 100%; pale yellow syrup.

¹H NMR. (500 MHz, CDCl₃): δ 1.29-1.43 (2H, m), 1.66-1.77 (2H, m),1.79-1.89 (2H, m), 2.12 (1H, td, J=11.2, 5.0 Hz), 2.27-2.35 m), 2.41 dd,J=17.4, 10.1 Hz), 2.54 (1H, d, J=17.4 Hz), 3.04-3.13 (2H, m), 3.56 (3H,s), 3.61 (1H, d, J=15.0 Hz), 3.63 (6H, s), 3.77 (3H, s), 3.81 (3H, s),6.29 (2H, s), 6.51 (1H, d, J=1.4 Hz), 6.67 (1H, dd, J=8.3, 1.4 Hz), 6.69(1H, d, J=8.3 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.4, 25.9, 33.4, 39.5,55.6 (2×C), 55.8, 56.0 (2×C), 57.9, 60.1, 60.8, 106.5 (2×C), 110.6,112.7, 120.4, 131.8, 131.9, 134.4, 136.4, 136.6, 147.4, 148.1, 152.7(2×C). IR (KBr) 3007, 2905, 1582, 1514 cm⁻¹. EIMS m/z (rel int) 439 (44,M⁺), 325 (100); HREIMS m/z calcd for C₂₆H₃₃NO₅: 439.2359; found:439.2351 [M]⁺.

2-(3,4-Dimethoxyphenyl)-3-(3-methoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine(11f)

Yield 100%; white powder, mp 106-107° C.

¹H NMR. (500 MHz, CDCl₃): δ 1.30-1.43 (2H, m), 1.69-1.77 (2H, m),1.79-1.89 (2H, m), 2.12 (1H, td, J=11.2, 4.2 Hz), 2.28-2.36 (1H, m),2.42 (1H, dd, J=17.2, 10.5 Hz), 2.53 (1H, d, J=17.2 Hz), 3.04-3.13 (2H,m), 3.52 (3H, s), 3.61 (3H, s), 3.62 (1H, d, J=16.6 Hz), 3.80 (3H, s),6.48 (1H, s), 6.60 t, J=1.4 Hz), 6.63-6.70 (4H, m), 7.07 (1H, t, J=7.4Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.3, 25.9, 33.3, 39.4, 55.1, 55.5,55.6, 55.7, 55.9, 60.2, 110.5, 112.1, 112.9, 114.7, 120.4, 121.5, 128.9,131.9 (2×C), 134.2, 142.4, 147.4, 147.9, 159.2. IR (KBr) 3060, 2924,1601, 1578, 1512 cm⁻¹. EIMS m/z (rel int) 379 (100, M⁺); HREIMS m/zcalcd for C₂₄H₂₉NO₃: 379.2147; found: 379.2142 [M]⁺.

Julandine (11g)

Yield 100%; white powder, mp 143-145° C. (M. A. Ciufolini, F.Roschangar, J. Am. Chem. Soc. 1996, 118, 12082-12089;⁾mp 135-137° C.).

¹H NMR (500 MHz, CDCl₃): δ1.29-1.40 (2H, m), 1.66-1.76 (2H, m),1.78-1.88 (2H, m), 2.10 (1H, td, J=11.3, 4.2 Hz), 2.26-2.33 (1H, m),2.39 (1H, dd, J=17.3, 11.7 Hz), 2.53 (1H, d, J=17.3 Hz), 3.01-3.11 (2H,m), 3.53 (3H, s), 3.60 (1H, d, J=16.6 Hz), 3.72 (3H, s), 3.80 (3H, s),6.46 (1H, s), 6.65-6.68 (2H, m), 6.69 (2H, d, J=8.7 Hz), 6.97 (2H, d,J=8.7 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.3, 25.9, 33.3, 39.5, 55.1,55.4, 55.6, 55.7, 57.9, 60.4, 110.4, 113.0, 113.4 (2×C), 120.5, 130.1(2×C), 131.2, 131.4, 133.2, 134.5, 147.2, 147.9, 158.0. IR (KBr) 3086,2932, 1605, 1574, 1512 cm⁻¹. EIMS m/z (rel int) 379 (55, M⁺), 265 (100);HREIMS m/z calcd for C₂₄H₂₉NO₃: 379.2147; found: 379.2154 [M]⁺.

3-(2,3,4-Trimethoxyphenyl)-2-(3,4-dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine(11h)

Yield 97%; pale yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.36-1.44 (2H, m), 1.71-1.77 (2H, m),1.81-1.89 (2H, m), 2.08-2.15 (1H, m), 2.32-2.40 (1H, m), 2.47-2.55 (2H,m), 3.06 (1H, d, J=11.6 Hz), 3.11 (1H, d, J=16.7 Hz), 3.50 (1H, d, J=163Hz), 3.59 (3H, s), 3.79 (3H, s), 3.80 (3H, s), 3.81 (3H, s), 3.82 (3H,s), 6.46 (1H, d, J=8.6 Hz), 6.54 (1H, d, J=1.8 Hz), 6.63 (1H, d, J=8.6Hz), 6.68 (1H, d, J=8.3 Hz), 6.71 (1H, dd, J=8.3, 1.8 Hz); ¹³C NMR (125MHz, CDCl₃): δ 24.4, 25.8, 33.2, 39.1, 55.4, 55.5, 55.7, 55.9, 57.9,60.3, 60.6, 60.7, 107.0, 110.4, 112.3, 120.0, 125.7, 127.5, 129.3,132.1, 134.5, 142.0, 147.2, 147.7, 151.6, 152.6. IR (KBr) 3021, 2936,1599, 1516 cm⁻¹. EIMS m/z (rel int) 439 (100, M⁺); HREIMS m/z calcd forC₂₆H₃₃NO₅: 439.2359; found: 439.2353 [M]⁺.

2,3-Bis(3,4-dimethoxyphenyl)-4,6,7,8,9,9a-hexahydro-1H-quinolizine (11i)

Yield 95%; white powder, mp 153-154° C.

¹H NMR (500 MHz, CDCl₃): δ 1.28-1.43 (2H, m), 1.70-1.78 (2H, m),1.78-1.90 (2H, m), 2.12 (1H, td, J=11.3, 4.8 Hz), 2.27-2.35 (1H, m) 2.39(1H, dd, J=17.3, 12.0 Hz), 2.54 (1H, d, J=17.3 Hz), 3.02-3.14 (2H, m),3.57 (3H, s), 3.60 (3H, s), 3.63 (1H, d, J=16.9 Hz), 3.80 (3H, s), 3.81(3H, s), 6.51 (1H, d, J=1.6 Hz), 6.55 (1H, d, J=1.65 Hz), 6.62-6.70 (4H,m); ¹³C NMR (125 MHz, CDCl₃): δ 24.4, 25.9, 33.4, 39.6, 55.5, 55.6,55.7, 55.8 (2×C), 57.9. 60.2. 110.6, 110.7, 112.8, 113.0, 120.6, 121.0,131.6 (2×C), 133.5, 134.6, 147.3, 147.5, 148.1, 148.3. IR (KBr) 3048,2943, 1601, 1582, 1520, 1501 cm⁻¹. EIMS m/z (rel int) 409 (73, M⁺), 165(100); HREIMS m/z calcd for C₂₅H₃₁NO₄: 409.2253; found: 409.2250 [M]⁺.

6. Synthesis of Compounds 4a-i and 5a-i by Oxidative Coupling

Typical procedure for the synthesis of compounds 4a-i and 5a-i by theoxidative coupling reaction of cis-stilbene derivatives 10a-i and 11a-i.Method A: A 0.04 M solution of stilbene derivatives 10b, 10c, 10f, 10g,10i, 11b, 11c, 11f, 11g, and 11i (0.2 mmol) in anhydrous CH₂Cl₂ (5 mL)was added to VOF₃ (1.0 mmol) at 0° C. and the mixture was stirred for 15min. TFA (2.8 mmol) was added and the purple mixture was stirred at 0°C. for 1 h.

Method B: A 0.04 M solution of stilbene derivatives 10a, 10d, 10e, 10h,11a, 11d, 11e, and 11h (0.2 mmol) in anhydrous CH₂Cl₂ (5 mL) was addedto VOF₃ (0.4 mmol) at −20° C. and the mixture was stirred for 15 min.TFA (1.1 mmol) was added and the purple mixture was stirred at −20° C.for 1 h. The reaction mixture was quenched with 10% aqueous NaOH. Then,the resulting mixture was warned to RT and stirred. for 5 min. Thebiphasic H₂O/CH₂Cl₂ mixture was separated and the H₂O layer wasextracted with CH₂Cl₂ (3×5 mL). The combined CH₂Cl₂ extracts were driedover anhydrous MgSO₄ and filtered. The filtrate was concentrated and theresidue was purified by column chromatography over silica gel by elutingwith a mixture of CHCl₃/MeOH (100:1 v/v), affording purephenanthroindolizidines 4a-i (and phenanthroquinolizidines 5a-i). Thecomplete spectral data of these compounds are given below.

1,2,3,6,7-Pentamethoxy-11,12,12a,13-tetrahydro-10H-9a-azacyclopenta[b]triphenylene(4a)

Yield 70%; white powder, mp 225-226° C.

¹H NMR (500 MHz, CDCl₃): δ 1.71-1.81 (1H, m), 1.86-1.96 (1H, m),1.99-2.09 (1H, m), 2.15-2.23 (1H, m), 2.26-2.35 (1H, m), 2.41 (1H, q,J=8.5 Hz), 3.24 (1H, dd, J=16.9, 11.0 Hz), 3.49 (1H, t, J=8.5 Hz), 3.68(1H, d, J=14.5 Hz), 3.77 (1H, d, J=16.9 Hz), 3.90 (3H, s), 4.00 (3H, s),4.05 (3H, s), 4.08 (3H, s), 4.09 (3H, s), 4.66 (1H, d, J=14.5 Hz), 7.15(1H, s), 7.68 (1H, s), 7.82 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 21.8,31.3, 37.0, 55.2, 55.6, 55.9, 56.0, 56.1, 60.7, 61.1, 61.5, 99.6, 103.0,104.0, 121.4, 123.1, 125.1, 126.4, 126.9, 127.6, 142.5, 148.5, 149.3,151.8, 151.9. IR (KBr) 3005, 2937, 1599, 1530, 1501 cm⁻¹. EIMS m/z (relint) 423 (40, M⁺), 354 (100); HREIMS m/z calcd for C₂₅H₂₉NO₅: 423.2046;found: 423.2041 [M]⁺.

Deoxypergutlarinine (4 b)

Yield 82%; white powder, mp 218-219° C. (G. Han, Y. Liu, Q. Wang, Org.Lett. 2013, 15, 533/1 5337; mp 225-228° C.).

¹NMR (500 MHz, CDCl₃): δ 1.70-1.81 (1H, m), 1.87-1.96 (1H, m), 1.98-2.08(1H, m), 2.19-2.28 (1H, m), 2.42-2.53 (2H, m), 2.94 (1H, dd, J=15.8,10.7 Hz), 3.42 (1H, dd, J=15.8, 2.8 Hz), 3.47 (1H, t, J=8.4 Hz), 3.65(1H, d, J=14.5 Hz), 4.01 (3H, s), 4.05 (3H, s), 4.10 (3H, s), 4.60 (1H,d, J=14.5 Hz), 7.16 (1H, s), 7.21 (1H, dd, J=9.0, 2.5 Hz), 7.89 (1H, d,J=2.5 Hz), 7.92 (1H, s), 7.95 (1H, d, J=9.0 Hz); ¹³C NMR (125 MHz,CDCl₃): δ 21.6, 31.3, 33.6, 54.0, 55.2, 55.5, 55.9, 56.0, 60.2, 103.2,104.0, 104.6, 114.8, 123.4, 125.2, 125.3, 125.6, 125.7, 127.0, 130.4,148.3, 149.4, 157.6. IR (KBr) 2959, 1616, 1531, 1512 cm⁻¹. EIMS m/z (relint) 363 (22, M⁺), 294 (100); HREIMS m/z calcd for C₂₃H₂₅NO₃: 363.1834;found: 363.1841 [M]⁺.

2,6,7-Trimethoxy-11,12,12a,13-tetrahydro-10H-9a-azacyclopenta[b]triphenylene(4c)

Yield 86%; white powder, mp 187-189° C.

¹H NMR (500 MHz, CDCl₃): δ 1.72-1.83 (1H,), 1.88-1.97 (1H, m), 1.99-2.10(1H, m), 2.20-2.29 (1H, m), 2.43-2.53 (2H, m), 2.91 (1H, dd, J=15.5,10.5 Hz), 3.37 (1H, dd, J=15.5, 2.5 Hz), 3.48 (1H, td, J=8.5, 1.7 Hz),3.68 (1H, d, J=14.8 Hz), 3.98 (3H, s), 4.05 (3H, s), 4.10 (3H, s), 4.63(1H, d, J=14.8 Hz), 7.16 (1H, s), 7.23 (1H, dd, J=9.0, 2.6 Hz), 7.35(1H, d, J=2.6 Hz), 7.94 (1H, s), 8.45 (1H, d, J=9.0 Hz); ¹³C NMR (125MHz, CDCl₃): δ 21.7, 31.3, 33.7, 54.2, 55.2, 55.4, 55.9, 56.0, 60.2,103.2, 103.4, 104.5, 115.5, 123.5, 123.8, 124.0, 124.2, 126.5, 128.3,132.2, 148.6, 148.7, 157.8. IR (KBr) 3098, 2932, 1620, 1612, 1516, 1501cm⁻¹. EIMS m/z (rel int) 363 (18, M⁺), 294 (100); HREIMS nez calcd forC₂₃H₂₅NO₃: 363.1834; found: 363.1839 [M]⁺.

4-Methoxytylophorine (4d)

Yield 89%; white powder, mp 193-194° C. (K. V. Rao, R. A. Wilson, B. M.Curnrnings, J. Pharma Sci. 1970, 59, 1501-1502; mp 198-200° C.).

¹H NMR (500 MHz, CDCl₃): δ 1.73-1.82 (1H, m), 1.88-1.96 (1H, m),1.99-2.08 (1H, m), 2.19-2.28 (1H, m), 2.41-2.52 (2H, m), 2.89 (1H, dd,J=14.8, 11.1 Hz), 3.02 (1H, d, J=14.6 Hz), 3.47 (1H, t, J=8.2 Hz), 3.67(1H, d, J=14.8 Hz), 3.99 (3H, s), 4.03 (3H, s), 4.04 (3H, s), 4.05 (3H,s), 4.09 (3H, s), 4.62 (1H, d, J=14.6 Hz), 7.17 (1H, s), 7.20 s), 9.20(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 21.6, 31.3, 34.2, 54.2, 55.2, 55.8(3×C), 60.3, 60.5, 61.4, 100.6, 102.6, 108.1, 118.0, 123.5, 125.0,126.3, 127.7, 128.8, 142.1, 147.9, 148.0, 151.6, 151.7. IR (KBr) 3021,2932, 1607, 1504 cm⁻¹. EIMS m/z (rel int) 423 (24, M⁺), 354 (100);HREIMS calcd for C₂₅H₂₉NO₅: 423.2046; found:423.2048 [M]⁺.

2,3,5,6,7-Pentamethoxy-11,12,12a,13-tetrahydro-10H-9a-azacyclopenta[b]triphenylene(4e)

Yield 85%; white powder, mp 169-170° C.

¹H NMR (500 MHz, CDCl₃): δ 1.75-1.83 (1H, m), 1.89-1.98 (1H, m),2.00-2.09 (1H, m), 2.21-2.29 (1H, m), 2.43-2.53 (2H, m), 2.93 (1H, dd,J=15.8, 10.4 Hz), 3.36 (1H, dd, J=15.8, 1.8 Hz), 3.48 (1H, t, J=8.2 Hz),3.66 (1H, d, J=14.4 Hz), 3.98 (3H, s), 4.03 (3H, s), 4.04 (3H, s), 4.06(3H, s), 4.09 (3H, s), 4.60 (1H, d, J=14.4 Hz), 7.04 (1H, s), 7.33 (1H,s), 9.19 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 21.6, 31.3, 34.0, 54.4,55.2, 55.7, 55.8, 55.9, 60.1, 60.5, 61.4, 99.6, 103.5, 108.0, 117.8,123.7, 125.9, 126.5, 127.3, 128.1, 142.0, 148.0, 148.1, 151.7, 151.8. IR(KBr) 3019, 2934, 1607, 1528, 1506 EIMS m/z (rel int) 423 (35, M⁺), 354(100); HREIMS m/z calcd for C₂₅H₂₉NO₅; 423.2046; found: 423.2052 [M]⁺.

Desmethoxytylophorine (4f)

Yield 85%; white powder, mp 196-197° C. (M. J. Niphakis, G I. Georg, M.J. Niphakis, Org. Lett. 2011, 13, 196-199; trip 203-205° C.).

¹H NMR (500 MHz, CDCl₃): δ 1.72-1.82 (1H, m), 1.87-1.97 (1H,), 1.99-2.09(1H, m), 2.19-2.28 (1H, m), 2.41-2.52 (2H, m), 2.91 (1H, dd, J=15.6,10.5 Hz), 3.36 (1H, dd, J=15.6, 2.5 Hz), 3.47 (1H, td, J=8.6, 1.8 Hz),3.65 (1H, d, J=14.7 Hz), 3.97 (3H, s), 4.05 (3H, s), 4.09 (3H, s), 4.63(1H, d, J=14.7 Hz), 7.20 (1H, d, J=2.5 Hz), 7.22 (1H, dd, J=9.0, 2.5Hz), 7.30 (1H, s), 7.92 (1H, s), 8.45 (1H, d, J=9.0 Hz); ¹³C NMR (125MHz, CDCl₃): δ 21.6, 31.3, 34.0, 54.0, 55.1, 55.4, 55.9, 56.0, 60.1,103.2, 103.8, 104.0, 115.3, 123.2, 124.1, 124.3, 125.3, 126.2, 128.7,130.6, 148.6, 148.7, 157.7. IR (KBr) 3017, 2920, 1616, 1501 cm⁻¹. EIMSm/z (rel int) 363 (43, M⁺), 294 (100); HREIMS calcd for C₂₃H₂₅NO₃:363.1834; found: 363.1835 [M]⁺.

Antofine (4g)

Yield 86%; white powder, mp 217° C. (decomp.) (M. J. Niphakis, G I.Georg, M. J. Niphakis, Org. Lett. 2011, 13, 196-199; mp 221-222° C.(decomp.)).

¹H NMR (500 MHz, CDCl₃): δ 1.73-1.83 m), 1.87-1.97 (1H, m.), 1.98-2.10(1H, m), 2.20-2.29 (1H, m), 2.41-2.56 (2H, m), 2.89 (1H, dd, J=14.2,11.0 Hz), 3.34 (1H, dd, J=14.2, 2.0 Hz), 3.46 (1H, t, J=8.0 Hz), 3.70J=14.8 Hz), 4.01 (3H, s), 4.06 (3H, s), 4.11 (3H, s), 4.69 (1H, d,J=14.8 Hz), 7.20 (1H, dd, J=9.0, 2.4 Hz), 7.31 (1H, s), 7.81 (1H d,j=9.0 Hz), 7.90 (1H, d, J=2.4 Hz), 7.91 (1H, s); ¹³C NMR (125 MHz,CDCl₃): δ 21.6, 31.3, 33.7, 53.9, 55.1, 55.5, 55.9, 56.0, 60.2, 103.8,104.0, 104.7, 114.9, 123.5, 124.1, 124.3, 125.5, 126.7, 127.1, 130.2,148.3, 149.4, 157.5. IR (KBr) 3106, 2947, 1616, 1531, 1512 cm⁻¹. EIMSm/z (rel int) 363 (26, M⁺), 294 (100); HREIMS m/z calcd for C₂₃H₂₅NO₃:363.1834; found: 363.1827 [M]⁺.

2,3,6,7,8-Pentamethoxy-11,12,12a,13-tetrahydro-10H-9a-azacyclopenta[b]triphenylene(4h)

Yield 54%; white powder, mp 231° C. (decomp.).

¹H NMR (500 MHz, CDCl₃): δ 1.70-1.79 (1H, m), 1.86-1.95 (1H, m),1.96-2.06 (1H, m), 2.22-2.30 (1H, m), 2.44 (1H, q, J=9.0 Hz), 2.45-2.53(1H, m), 2.95 (1H, dd, J=15.8, 10.5 Hz), 3.34-3.45 (2H, m), 3.89 (1H, d,J=16.3 Hz), 3.95 (3H, s), 3.98 (3H, s), 4.05 (3H, s), 4.08 (3H, s), 4.09(3H, s), 4.93 (1H, d, J=16.3 Hz), 7.29 (1H, s), 7.67 (1H, s), 7.80 (1H,s); ¹³C NMR (125 MHz, CDCl₃): δ 21.7, 31.7, 35.0, 55.2, 55.8, 55.9,56.0, 56.7, 59.6, 61.0, 61.4, 99.7, 103.8, 103.9, 120.1, 123.2, 126.6(2×C), 126.7, 127.5, 142.2, 148.5, 149.2, 151.4, 151.8. IR (KBr) 3009,2932, 1609, 1572, 1526 cm⁻¹. EIMS m/z^(.) (rel int) 423 (53, M^(±)) 354(100); HREIMS m/z calcd for C₂₅H₂₉NO₅: 423.2046; found: 423.2040_([)M]⁺.

Tylophorine (4i)

Yield 85%; white powder, mp 270° C. (decomp) ('I′. H. Chuang, S. J. Lee,C. W. Yang, P. L. Wu, Org. Biomol. Chem. 2006, 4, 860-867; mp 270° C.(decomp.)).

¹H NMR (500 MHz, CDCl₃): δ 1.71-1.83 (1H, m), 1.87-1.96 (1H, m),1.98-2.09 (1H, m), 2.19-2.27 (1H, m), 2.41-2.51 (2H, m), 2.89 (1H, dd,J=15.6, 10.5 Hz), 3.34 (1H, dd, J=15.6, 2.7 Hz), 3.47 (1H, td, J=8.5,1.9 Hz), 3.64 (1H, d, J=14.6 Hz), 4.04 (3H, s), 4.05 (3H, s), 4.11 (6H,s), 4.60 (1H, d, J=14.6 Hz), 7.14 (1H, s), 7.29 (1H, s), 7.80 (1H, s),7.81 (1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 21.6, 31.3, 33.8, 54.1, 55.2,55.8, 55.9, 56.0 (2><C), 60.2, 103.2, 103.4, 103.5, 104.0, 123.4, 123.6,124.4, 125.9, 126.1, 126.3, 148.4, 148.5, 148.7 (2><C). IR (KBr) 3094,2928, 1620, 1512 cm⁻¹. EIMS m/z (rel int) 393 (26, M³⁰), 324 (100);HREIMS m/z calcd for C₂₄H₂₇NO₄: 393.1940; found: 393.1943 [M]⁺.

1,2,3,6,7-Pentamethoxy-10,11,12,13,13a,14-hexahydro-9/1-9a-azabenzo [b]triphenylene (5a)

Yield 77%; white powder, mp 191-192° C.

¹H NMR (500 MHz, CDCl₃): δ 1.36-1.47 (1H, m), 1.47-1.57 (1H, m),1.72-1.92 (3H, m), 1.96-2.03 (1H, m), 2.16-2.30 (2H, m), 3.23 (1H, dd,J=17.4, 10.7 Hz), 3.30 (1H, d, J=10.7 Hz), 3.54-3.65 (2H, m), 3.90 (3H,s), 3.99 (3H, s), 4.05 (3H, s), 4.08 (3H, s), 4.09 (3H, s), 4.40 (1H, d,J=15.3 Hz), 7.12 (1H, s), 7.67 (1H, s), 7.82 (1H, s); NMR (125 MHz,CDCl₃): δ 24.3, 25.9, 33.6, 37.8, 55.9 (2×C), 56.0, 56.4, 57.0, 57.7,61.1, 61.4, 99.6, 102.8, 104.1, 120.7, 123.0, 124.6, 125.1, 126.6,126.8, 142.4, 148.3, 149.2, 151.8 (2×C). IR (KBr) 3059, 2922, 1609,1531, 1503 cm⁻¹. EIMS m/z (rel int) 437 (43, M⁺) 354 (100); HREIMS m/zcalcd for C₂₆H₃₁NO₅: 437.2202; found: 437.2208 [M]⁺.

Boehmeriasin A (5b)

Yield 88%; white powder, mp 217-219° C. (Q. Wang, Z. Wang, TetrahedronLett. 2010, 51, 1377-1379; mp 222-223° C.).

¹H NMR (500 MHz, CDCl₃): δ 1.39-1.58 (2H, m), 1.75-1.85 (2H, m),1.85-1.92 (1H, m), 1.99-2.06 (1H, m), 2.31 (1H, td, 1=10.9, 3.6 Hz),2.36-2.43 (1H, m), 2.93 (1H, dd, J=16.3, 10.2 Hz), 3.18 (1H, dd, J=16.3,2.2 Hz), 3.29 (1H, d, J=10.9 Hz), 3.59 (1H, d, J=15.1 Hz), 4.01 (3H, s),4.05 (3H, s), 4.10 (3H, s), 4.34 (1H, d, J=15.1 Hz), 7.13 (1H, s), 7.20(1H, dd, J=9.0, 2.3 Hz), 7.87-7.95 (3H, m), 7.92 (1H, s); NMR (125 MHz,CDCl₃): δ 24.3, 26.0, 33.7, 34.7, 55.5, 55.9, 56.0, 56.2, 56.4, 57.5,103.1, 104.1, 104.6, 114.7, 123.3, 124.2, 125.0, 125.2, 125.9, 130.3,148.2, 149.4, 157.5. IR (KBr) 3001, 2920, 1612, 1512 cm⁻¹. EIMS m/z (relint) 377 (23, M⁺), 294 (100); HREIMS m/z calcd for C₂₄H₂₇NO₃: 377.1991;found: 377.2000 [M]⁺.

2,6,7-Trimethoxy-10,11,12,13,13a,14-hexahydro-9H-9a-azabenzo[b]triphenylene(5c)

Yield 84%; white powder, mp 182-184° C.

¹H NMR (500 MHz, CDCl₃): δ 1.39-1.59 (2H, m), 1.75-1.85 (2H, m),1.85-1.92 (1H, m), 2.00-2.06 (1H, m), 2.31 (1H, td, J=11.2, 3.3 Hz),2.34-2.41 (1H, m), 2.89 (1H, dd, J=16.5, 11.2 Hz), 3.11 (1H, dd, J=16.5,3.4 Hz), 3.29 (1H, d, J=11.2 Hz), 3.60 (1H, d, J=15.5 Hz), 3.97 (3H, s),4.04 (3H, s), 4.09 (3H, s), 4.36 (1H, d, J=15.5 Hz), 7.13 (1H, s), 7.22(1H, dd, J=9.1, 2.6 Hz), 7.29 (1H, d, J=2.6 Hz), 7.93 (1H, s), 8.43 (1H,d, J=9.1 Hz); ¹³C NMR (125 MHz, CDCl₃): δ 24.4, 26.0, 33.8, 34.7, 55.4,55.9, 56.0, 56.3 (2×C), 57.5, 103.1, 103.4, 104.5, 115.3, 123.3, 123.4,124.0, 124.1, 125.4, 127.2, 131.6, 148.5, 148.6, 157.7. IR (KBr) 3098,2924, 1616, 1508 cm ⁻¹. EIMS m/z (rel int) 377 (21, M⁺), 294 (100);HREIMS m/z calcd for C₂₄H₂₇NO₃: 377.1991; found: 377.1986 [M]⁺.

4,7-Diniethoxycryptoplerine (5d)

Yield 90%; white powder, mp 101-102° C.

¹H NMR (500 MHz, CDCl₃): δ 1.39-1.50 (1H,), 1.50-1.60 (1H, m), 1.76-1.85(2H, m), 1.85-1.93 (1H, m), 2.00-2.08 (1H, m), 2.31 (1H, td, J=11.2, 4.0Hz), 2.35-2.44 (1H, m), 2.90 (1H, dd, J=16.0, 11.0 Hz), 3.07 (11-1, dd,J=16.0, 3.2 Hz), 3.29 (1H, d, J=11.2Hz), 3.61 (1H, d, J=15.4 Hz), 3.98(3H, s), 4.03 (3H, s), 4.04 (6H, s), 4.08 (3H, s), 4.37 (1H, d, J=15.4Hz), 7.13 (1H, s), 7.14 (1H, s), 9.19 (1H, s); ¹³C NMR (125 MHz, CDCl₃):δ 24.2, 25.8, 33.6, 35.1, 55.7, 55.8, 55.9, 56.2, 56.4, 57.6, 60.5,61.3, 100.5, 102.5, 108.2, 117.9, 123.5, 124.5, 125.1, 126.5, 128.2,142.1, 147.9, 148.0, 151.7 (2×C). IR (KBr) 3017, 2934, 1609, 1506 cm⁻¹.EIMS m/z (rel int) 437 (24, M⁺), 354 (100); HREIMS m/z calcd forC₂₆H₃₁N₅: 437.2202; found:437.2206 [M]⁺.

2,3,5,6,7-Pentamethoxy-10,11,12,13,13a,14-hexahydro-9H-9a-azabenzo[b]triphenylene(5e)

Yield 88%; white powder, mp 1.66-167° C.

¹H NMR (500 MHz, CDCl₃): δ 1.39-1.59 (2H, m), 1.75-1.86 (2H, m),1.86-1.93 (1H, m), 2.00-2.08 (1H, m), 2.31 (1H, td, J=11.3, 3.7 Hz),2.35-2.42 (1H, m), 2.92 (1H, dd, J=16.5, 11.1 Hz), 3.12 (1H, dd, J=16.5,3.5 Hz), 3.29 (1H, d, J=11.3 Hz), 3.59 (1H, d, J=15.2 Hz), 3.98 (3H, s),4.03 (3H, s), 4.04 (3H, s), 4.06 (3H, s), 4.08 (3H, s), 4.34 (1H, d,J=15.2 Hz), 7.01 (1H, s), 7.28 (1H, s), 9.18 (1H, s); ¹³C NMR (125 MHz,CDCl₃): δ 24.3, 25.9, 33.7, 35.1, 55.7, 55.8, 55.9, 56.3, 56.6, 57.4,60.5, 61.3, 99.5, 103.3, 108.1, 117.7, 123.5, 124.8, 125.9, 126.9,127.0, 141.9, 147.9, 148.0, 151.7, 151.8. IR (KBr) 3055, 2930, 1609,1524, 1501 cm⁻¹. EIMS (rel int) 437 (32, M⁺), 354 (100); HREIMS m/zcalcd for C₂₆H₃₁NO₅: 437.2202; found: 437.2208 [M]⁺.

2,3,7-Trimethoxy-10,11,12,13,13a,14-hexahythdro-9H-9a-azabenzo[b]triphenylene(5f)

Yield 86%; white powder, mp 156-158° C.

¹H NMR (500 MHz, CDCl₃): δ 1.37-1.58 (2H, m), 1.72-1.93 (3H, m),1.98-2.05 (1H, m), 2.24-2.39 (2H, m), 2.87 (1H, dd, J=16.6, 12.3 Hz),3.07 (1H, d, J=16.6 Hz), 3.27 (1H, d, J=10.8 Hz), 3.56 (1H, d, J=15.2Hz), 3.96 (3H, s), 4.04 (3H, s), 4.08 (3H, s), 4.35 (1H, d, J=15.2 Hz),7.16 (1H, s), 7.18-7.25 (2H, m), 7.90 (1H, s), 8.43 (1H, d, J=8.8 Hz);¹³C NMR (125 MHz, CDCl₃): δ 24.4, 26.0, 33.8, 35.0, 55.4, 55.9, 56.0,56.1, 56.3, 57.4, 103.3, 103.8, 103.9, 115.0, 123.2, 124.1, 124.2,124.7, 125.1, 127.6, 130.2, 148.5, 148.7, 157.7. IR (KBr) 3102, 2920,1616, 1508 cm⁻¹. EIMS m/z (rel int) 377 (44, M⁺), 294 (100); HREIMS m/zcalcd for C₂₄H₂₇NO₃: 377.1991; found: 377.2000 [M]⁺.

Cryptopleurine (5g)

Yield 88%; white powder, mp 197° C. (decomp.) (S. Kim, Y. M. Lee, J.Lee, T. Lee, Y. Fu, Y. Song, J. Cho, D. Kim, J. Org. Chem. 2007, 72,4886 4891; mp 177-179° C.).

¹H NMR (500 MHz, CDCl₃): δ 1.38-1.60 (2H, m), 1.75-1.85 (2H, 1.85-1.93(1H, m), 1.99-2.07 (1H, m), 2.30 (1H, td, J=11.0, 3.6 Hz), 2.35-2.45(1H, m), 2.88 (1H, dd, J=16.0, 11.0 Hz), 3.07 (1H, dd, J=16.0, 4.0 Hz),3.27 (1H, d, J=11.0 Hz), 3.63 (1H, d, J=15.3 Hz), 4.01 (3H, s), 4.05(3H, s), 4.09 (3H, s), 4.43 (1H, d, J=15.3 Hz), 7.18 (1H, dd, J=9.0, 2.4Hz), 7.24 (1H, s), 7.78 (1H, d, J=9.0 Hz), 7.88 (1H, d, J=2.4 Hz), 7.89(1H, s); ¹³C NMR (125 MHz, CDCl₃): δ 24.3, 25.9, 33.7, 34.6, 55.5, 55.9,56.0 (2×C), 56.2, 57.6, 103.8, 103.9, 104.8, 114.8, 123.4, 123.7, 124.1,124.4, 125.5, 126.5, 130.1, 148.3, 149.4, 157.4. IR (KBr) 3005, 2936,1612, 1531, 1512 cm⁻¹. EIMS m/z (rel int) 377 (25, M⁺), 294 (100);HREIMS m/z caled for C₂₄H₂₇NO₃: 377.1991; found: 377.1990 [M]⁺.

2,3,6,7,8-Pentamethoxy-10,11,12,13,13a,14-hexahydro-91/-9a-azabenzo[b]triphenylene (5h)

Yield 71%; white powder, mp 211° C. (decomp.).

¹H NMR (500 MHz, CDCl₃): δ 1.41-1.54 (2H, m), 1.75-1.81 (2H,), 1.84-1.90(1H, m), 2.02-2.08 (1H, m), 2.28 (1H, td, J=11.3, 3.4 Hz), 2.36-2.44(1H, m), 2.92 (1H, dd, J=16.2, 3.4 Hz), 3.14 (1H, dd, J=16.2, 2.6 Hz),3.25 (1H, d, J=11.3 Hz), 3.84 (1H, d, J=16.5 Hz), 3.94 (3H, s), 3.98(3H, s), 4.06 (3H, s), 4.08 (3H, s), 4.09 (3H, s), 4.74 (1H, d, J=16.5Hz), 7.25 (1H, s), 7.67 (1H, s), 7.80 (1H, s); ¹³C NMR (125 MHz, CDCl₃):δ 24.3, 26.0, 34.0, 35.6, 55.9, 56.0 (2×C), 56.1, 57.0, 58.6, 61.0,61.4, 99.7, 103.8, 103.9, 119.7, 123.2, 125.4, 126.1, 126.6, 126.7,142.2, 148.5, 149.2, 151.2, 151.7. IR (KBr) 3021, 2932, 1601, 1530, 1501cm⁻¹. ElMS m/z (rel int) 437 (58, M⁺), 354 (100); HREIMS m/z calcd forC₂₆H₃₁NO₅: 437.2202; found: 437.2209 _([)M]⁺.

7-Methoxycryptopleurine (5i)

Yield 92%; white powder, mp 246-248° C. (T. H. Chuang, S. J. Lee, C. W.Yang, P. L. Wu, Org. Biomol. Chem. 2006, 4, 860-867; mp 245-247° C.(decomp.)).

¹H NMR (500 MHz, CDCl₃): δ 1.40-1.60 (2H, m), 1.75-1.86 (2H, m),1.86-1.94 (1H, m), 2.00-2.08 (1H, m), 2.32 (1H, td, J=11.1, 3.5 Hz),2.36-2.45 (1H, m), 2.91 (1H, dd, J=16.5, 11.5 Hz), 3.13 (1H, dd, J=16.5,3.9 Hz), 3.30 (1H, d, J=11.1 Hz), 3.62 (1H, d, J=15.1 Hz), 4.05 (3H, s),4.06 (3H, s), 4.11 (6H, s), 4.37 (1H, d, J=15.1 Hz), 7.14 (1H, s), 7.26(1H, s), 7.82 (1H, s), 7.83 (1H, s); NMR (125 MHz, CDCl₃): δ 24.4, 26.0,33.8, 34.9, 55.9, 56.0, 56.1 (2×C), 56.3, 56.4, 57.6, 103.1, 103.4,103.6, 103.9, 123.4, 123.5, 123.9, 125.0, 125.3 (2×C), 148.4, 148.5,148.7 (2×C). IR (KBr) 3094, 2920, 1620, 1531, 1512 cm⁻¹. EIMS m/z (relint) 407 (23, M⁺), 324 (100); HREIMS m/z calcd for C₂₅H₂₉NO₄: 407.2097;found: 407.2096 [M]⁺.

7. Synthesis of 7-hydroxyeryptopi (20)

NaBH₄ (283.8 mg, 7.5 mmol) was carefully added to a stirred solution of3-benzyloxy-4methoxybenzaldehyde (1.21 g, 5.0 mmol) in MeOH (25 mL) at0° C. The mixture was stirred at RT under N₂ for 1 h. TFA (2.8 mmol) wasadded, and the purple mixture was stirred at 0° C. for 1 h. The solventwas evaporated under reduced pressure. Then, the residue was dilutedwith a saturated aqueous NH₄Cl solution (25 mL) and extracted with EtOAc(5×20 mL). The combined organic extract was washed with H2O (3×20 Mt),dried over anhydrous MgSO₄, and filtered. The filtrate was concentrated,and the residue was purified by column chromatography over silica gel byeluting with a mixture of hexane/EtOAc (1:1 v/v), affording purecompound S3.

(3-Benzyloxy-4-methoxyphenyl)methanol (S3)

Yield 86%; white needle, mp 73-74° C. (hexane-EtOAc) (A. R. Battersby,R. Binks, R. J. Francis, D. J. McCaldin, H. Rainuz, J. Chem. Soc. 1964,3600-3610; mp 72-73° C.).

¹H NMR (500 MHz, CDCl₃): δ 2.59 (1H, br s), 3.78 (3H, s), 4.42 (2H, s),5.04 (2H, s), 6.78 (1H, d, J=8.2 Hz), 6.81 (1H, dd, J=8.2, 1.7 Hz), 6.88(1H, d, J=1.7 Hz), 7.25 (1H, t, J=7.4 Hz), 7.31 (2H, t, J=7.4 Hz), 7.39(2H, d, J=7.4 Hz). ¹³C NMR (125 MHz, CDCl₃): δ 55.8, 64.5, 70.7, 111.6,112.9, 119.7, 127.2 (2×C), 127.6, 128.3 (2×C), 133.5, 136.9, 148.0,148.9. IR (KBr) 3356, 3021, 2963, 1609, 1508 cm⁻¹. EIMS m/z (rel int)244 (14, M⁺), 91 (100). HREIMS calcd for C₁₅H₁₆O₃: 244.1099; found:244.1090 [M]⁺.

A 1.0 M solution of thionyl chloride in CH₂Cl₂ (6.0 mL, 6.0 mmol) wasadded to a solution of alcohol S3 (977.0 mg, 4.0 mmol) in CH₂Cl₂ (20mL), and the mixture was stirred at RT under N₂ for 2 h. The solvent wasevaporated under reduced pressure, affording the corresponding chloridequantitatively. Without further purification, the chloride was dissolvedin anhydrous CH₃CN (20 mL), and KCN (390.7 mg, 6.0 mmol) and 18-crown-6(42.3 mg, 0.16 mmol) were added. The suspension was refluxed under N₂for overnight. The solvent was evaporated under reduced pressure. Then,the residue was diluted with H₂O (25 mL) and extracted with EtOAc (5×20mL). The combined organic extract was washed with H₂O (3×20 mL), driedover anhydrous MgSO₄, and filtered. The filtrate was concentrated, andthe residue was purified by column chromatography over silica gel byeluting with a mixture of hexane/EtOAc (5:1 v/v), affording purecompound S4.

2-(3-Benzyloxy-4-methoxyphenyl)acetonitrile (S4)

Yield 90%; white needle, mp 83-84° C. (hexane-EtOAc) (A. R. Battersby,R. Binks, R. J. Francis, D. I McCaldin, H. Ramuz, J. Chem. Soc. 1964,3600-3610; mp 79.5-80.5° C.).

¹H NMR (500 MHz, CDCl₃): δ 3.63 (2H, s), 3.88 (3H, s), 5.15 (2H, s),6.83-6.88 (3H, m), 7.31 (1H, t, J=7.3 Hz), 7.37 (2H, t, J=7.3 Hz), 7.44(2H, d, J=7.3 Hz). ¹³C NMR (125 MHz, CDCl₃): 23.1, 56.1, 71.2, 112.2,113.9, 118.0, 120.8, 122.1, 127.4 (2×C), 128.0, 128.6 (2×C), 136.7,148.6, 149.6. IR (KBr) 3017, 2940, 2839, 2253, 1597, 1512 cm ^(−1.) EIMSm/z (rel int) 253 (100, HREIMS anitz calcd for C₁₆H₁₅NO₂: 253.1103;found: 253.1101 [M]⁺.

The typical procedure for the synthesis of (Z)-2,3-diphenyla rylonitrile17 was used and. the resulting precipitate was filtered, affording purecompound S5.

Yield 98%; yellow needle, mp 71-72° C. (hexane-Et(Ac).

¹H NMR (500 MHz, CDCl₃): δ 3.92 (3H, s), 3.93 (314, s), 3.96 (3H, s),5.20 (2H, s), 6.90 (1H, d, J=8.4 Hz), 6.92 (1H, d, J=8.4 Hz), 7.18 s),7.21-7.25 (2H, m), 7.27-7.35 (2H, m), 7.39 (2H, t, J=7.5 Hz), 7.48 (2H,d, J=7.5 Hz), 7.65 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 55.9, 56.0,56.1, 71.4, 108.4, 110.7, 111.0, 111.8, 111.9, 118.7, 119.3, 124.0,126.9, 127.5 (2×C), 127.6, 128.0, 128.6 (2×C), 136.7, 140.3, 148.4,149.0, 150.5, 150.9. IR (KI3r) 3017, 2932, 2207, 1597, 1520 cm⁻¹. EIMSm/z (rel hit) 401 (47, M⁺), 91 (100). HREIMS m/z calcd for C₂₅H₂₃NO₄:401.1627; found: 401.1619 [M]⁺.

The typical. procedure for the synthesis of(E)-2,3-diphenylacrylaldehydes 16 was used, and the crude product waspurified by column chromatography over silica gel by eluting with amixture of hexane/EtOAc (3:1 v/v), affording pure(E)-2,3-diphenylacrylaldehyde S6 as the major product.

(E)-2-(3-Benzyloxy-4-methoxyphenyl)-3-(3,4-dimethoxyphenyl)acrylaldehyde(S6)

Yield 86%; yellow granule, mp 114-115° C. (hexane-EtOAc).

¹H NMR (500 MHz, CDCl₃): δ 3.45 (3H, s), 3.87 (3H, s), 3.89 (3H, s),5.06 (2H, s), 6.63 (1H, s), 6.75 (1H, d, J=8.3 Hz), 6.79 (1H, s), 6.81(1H, d, .J=8.3 Hz), 6.92 (1H, d, J=8.1 Hz), 6.97 (1H, d, J=8.1 Hz), 7.23(1H, t, J=7.4 Hz), 7.25 (1H, s), 7.28 (2H, t, J=7.4 Hz), 7.37 (2H, d,J=7.4 Hz), 9.68 (1H, s). ¹³C NMR (125 MHz, CDCl₃): δ 55.1, 55.8, 56.0,70.9, 110.5, 112.3, 112.4, 115.2, 122.5, 125.6, 126.1, 126.9, 127.3(2×C), 127.7, 128.3 (2×C), 136.7, 139.4, 148.3, 148.6, 149.6, 150.1,150.9, 193.8. IR (KBr) 3017, 2932, 2839, 2708, 1678, 1597, 1512 cm⁻¹.EIMS m/z (rel int) 404 (47, M⁺), 91 (100). HREIMS m/z calcd forC₂₅H₂₄O₅: 404.1624; found: 404.1633 [M]⁺.

The typical procedure for the synthesis of a-iminonitriles 15a-i wasused., and the crude product was purified by a short columnchromatography over silica gel by eluting with a mixture of hexane/EtOAc(4:1 v/v), affording pure compound S7.

(3E)-3 -(3 -B enzyloxy-4-methoxy⁻phenyl)-2-(5-hexenylimino)-4-(3,4-dimethoxyphenyl)-3-butenenitrile (S7)

Yield 80%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.44 (2H, quintet, J=7.2 Hz), 1.66 (2H,quintet, J=7.2 Hz), 2.08 (2H, q, J=7.2 Hz), 3.44 (3H, s), 3.85 (3H, s),3.86 (2H, t, J=7.2 Hz), 3.89 (3H, s), 4.95 (1H, d, J=10.2 Hz), 5.00 (1H,d, J=17.1 Hz), 5.05 (2H, s), 5.79 (1H, ddt, J=17.1, 10.2, 7.2 Hz), 6.41(1H, d, J=1.6 Hz), 6.69 (1H, d, J=8.4 Hz), 6.74 (1H, s), 6.74-6.78 (2H,m), 6.93 (1H, d, J=7.9 Hz), 7.23 (1H, t, J=7.3 Hz), 7.28 (2H, t, J=7.3Hz), 7.35 (2H, 7.3 Hz), 7.41 (1H, s). ¹³C NMR (125 MHz, CDCl₃); δ 26.5,29.8, 33.3, 55.1, 55.7, 55.9, 58.7, 70.9, 109.6, 110.5, 112.1, 1123,114.7, 115.8, 123.0, 124.9, 127.2 (2×C), 127.5, 127.7, 127.8, 128.4(2×C), 135.9, 136.7, 138.4, 139.7, 144.8, 148.1, 148.5, 149.5, 149.8. IR(KBr) 3017, 2936, 2218, 1574, 1508 cm⁻¹. EIMS m/z (rel int) 510 (43,M⁺), 91 (100). HREIMS m/z calcd for C₃₂H₃₄N₂O₄: 510.2519; found:510.2522 [M]⁺.

The typical. procedure for IADA was used, and the crude product waspurified by column chromatography over silica gel by eluting with amixture of hexane/EtOAc (3:1 v/v), affording cycloadducts S8.

trans-3-(3-Benzyloxy-4-methoxyphenyl)-2-(3,4-dimethoxyphenyl)-2,6,7,8,9,9a-hexahydro-1Hquinolizine-4-carbonitrile (S8)

Yield 95%; yellow syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.23-1.34 (2H, m), 1.48-1.63 (2H, m),1.69-1.81 (3H, m), 2.02 (1H, td, J=13.0, 5.0 Hz), 2.55-2.63 (1H, m),2.66 (1H, td, J=11.8, 2.4 Hz), 3.70 (1H, d, J=5.0 Hz), 3.80 (3H, s),3.81 (3H, s), 3.85 (3H, s), 3.98 (1H, d, J=11.8 Hz), 5.00 (1H, d, J=12.4Hz), 5.03 (1H, d, J=12.4 Hz), 6.63 (1H, d, J=1.9 Hz), 6.69 (1H, dd,J=8.4, 1.9 Hz), 6.75 (1H, d, J=8.4 Hz), 6.78 (1H, d, J=8.4 Hz), 6.82(1H, d, J=2.1 Hz), 6.90 (1H, dd, J=8.4, 2.1 Hz), 7.25-7.33 (5H, rn). ¹³CNMR (125 MHz, CDCl₃): δ 23.9, 25.8, 31.8, 37.3, 43.1, 50.7, 51.4, 55.6,55.7 (2×C), 70.9, 110.9, 111.2, 111.4, 114.3, 115.9, 120.3, 120.7,121.6, 127.1 (2×C), 127.5, 128.3 (2×C), 131.7, 137.0, 137.2, 147.4,147.5, 148.7, 149.0. IR (KBr) 3017, 2940, 2214, 1597, 1512 cm⁻¹. EIMSm/z (rel int) 510 (100, M⁺). HREIMS m/z calcd for C₃₂H₃₄N₂O₄: 510.2519;found: 510.2518 [M]⁺.

The typical procedure for the synthesis of cis-stilbene derivatives11a-i by reductive decyanization was used and the crude product waspurified by column chromatography over silica gel by eluting with EtOAc,affording pure stilbene derivative S9.

3-(3-Benzyloxy-4-methoxyphenyl)-2-(3,4-dimethoxypheny-4,6,7,8,9,9a-hexahydro-1 H-quinolizine (S9)

Yield 95%; white syrup.

¹H NMR (500 MHz, CDCl₃): δ 1.28-1.40 (2H, m), 1.67-1.75 (2H, m.),1.78-1.86 (2H, m), 2.09 (1H, td, J=11.3, 5.0 Hz), 2.25-2.32 (1H, m.),2.37 (1H, dd, J=17.1, 10.0 Hz), 2.50 (1H, d, J=17.1 Hz), 3.00 (1H, d,J=16.6 Hz), 3.07 (1H, d, J=11.3 Hz), 3.53 (3H, s), 3.54 (1H, d, J=16.6Hz), 3.80 (3H, s), 3.81 (3H, s), 4.83 (1H, d, J=12.4 Hz), 4.88 d, J=12.4Hz), 6.45 (1H, d, J=1.8 Hz), 6.59-6.62 (2H, m), 6.62-6.67 (2H, m), 6.69(1H, d, J=8.3 Hz), 7.26-7.34 (5H, m). ¹³C NMR (125 MHz, CDCl₃): δ 24.3,25.9, 33.3, 39.5, 55.5 (2×C), 55.7, 55.9, 57.9, 60.1, 71.0, 110.6,111.4, 112.7, 115.7, 120.6, 121.8, 127.1 (2×C), 127.7, 128.4 (2×C),131.3, 131.4, 133.4, 134.6, 137.2, 147.3, 147.6, 148.1, 148.2. IR. (KBr)3017, 2932, 1589, 1512 cm⁻¹. EIMS m/z (rel int) 485 (61, M⁺), 91 (100).HREIMS m/z calcd for C₃₁H₃₅NO₄: 485.2566; found: 485.2562 [M]⁺.

The typical procedure for oxidative coupling reaction (method A) wasused and the crude product was purified by column chromatography oversilica gel by eluting with a mixture of CHCl_(3/)MeOH (100:1 v/v),affording pure Bn-protected phenanthroquinolizidine S10.

7-Benzyloxy-2,3,6-trimethoxy-10,11,12,13,13a,14-hexahydro-9H-9a-azabenzo[b]triphenylene (510)

Yield 96%; white solid, mp 207° C. (demcomp.).

¹H NMR (500 MHz, CDCl₃): δ 1.36-1.56 (2H, m), 1.71-1.83 (2H, m),1.83-1.90 (1H, m), 1.96-2.03 (1H, m), 2.21-2.36 (2H, m), 2.83 (1H, dd,J=16.0, 10.6 Hz), 3.02 (1H, d, J=16.0 Hz), 3.22 (1H, d, J=10.7 Hz), 3.44(1H, d, J=15.1 Hz), 4.02 (3H, s), 4.08 (3H, s), 4.09 (3H, s), 4.17 (1H,d, J=15.1 Hz), 5.28 (2H, s), 7.15 (1H, s), 7.19 (1H, s), 7.31 (1H, t,J=7.4 Hz), 7.38 (2H, t, J=7.4 Hz), 7.52 (2H, d, J=7.4 Hz), 7.78 (1H, s),7.81 (1H, s). ¹³C NMR (125 MHz, CDCl₃); δ 24.3, 25.9, 33.7, 34.7, 55.9,56.0, 56.1, 56.2 (2×C), 57.5, 71.3, 103.5, 103.9, 104.1, 106.4, 123.5,123.7, 123.8, 124.9, 125.1, 125.3, 127.6 (2×C), 128.0, 128.6 (2×C),137.1, 147.7, 148.4, 148.7, 149.0. IR (KBr) 3017, 2936, 1616, 1512 cm⁻¹.EIMS m/z (rel int) 483 (39, M⁺), 309 (100). HREIMS m/z calcd forC₃₁H₃₃NO₄: 483.2410; found: 483.2418 [M]⁺.

A mixture of Bn-protected phenanthroquinolizidine S10 (96.7 mg, 0.2mmol), 10% Pd/C (10 mg), AcOH (0.2 mL), and MeOH (20 mL) was stirred at50° C. for overnight under H₂ (50 psi) in a Parr high-pressure vessel.The mixture was filtered and concentrated under reduced pressure. Theresidue was diluted with CH₂Cl₂ (30 mL), washed with saturated NaHCO₃(10 mL) and H₂O (3×10 mL), dried. over anhydrous MgSO₄, and filtered.The filtrate was concentrated, and the residue was purified by columnchromatography over silica gel by eluting with a mixture of CHCl₃/MeOH(30:1 v/v), affording pure phenanthroquinolizidine 20.

7-Hydroxy-2,3,6-trimethoxy-10,11,12,13,13a,14-hexahydro-911-9a-azabenzo[b]triphenylene (20)

Yield 90%; white solid, mp 114-1.1.5° C.

¹H NMR (500 MHz, CDCl₃): δ 1.39-1.49 (1H, m), 1.51-1.61 (1H, m),1.74-1.84 (2H, m), 1.85-1.92 (1H, m), 1.99-2.05 (1H, m), 2.24-2.33 (1H,m), 2.34-2.42 (1H, m), 2.89 (1H, dd, J=16.4, 10.5 Hz), 3.06 (1H, dd,J=16.4, 3.5 Hz), 3.27 (1H, d, J=10.9 Hz), 3.52 (1H, d_(;) J=15.2 Hz),4.03 (3H, s), 4.04 (3H s), 4.08 (3H, s), 4.32 (1H, d, J=15.2 Hz), 7.21(1H, s), 7.26 (1H, s), 7.65 (1H, s), 7.71 (1H, s). ¹³C NMR (125 MHz,CDCl₃): δ 24.3, 25.8, 33.6, 34.6, 55.9 (2×C), 56.0, 56.1 (2×C), 57.6,102.5, 103.4, 104.0, 106.8, 123.1, 123.6, 124.3, 124.9, 125.0, 125.1,145.1, 146.5, 148.4, 148.6. IR (KBr) 3395, 3013, 2932, 1616, 1504 cm⁻¹.EIMS m/z (rel int) 393 (26, M⁺), 310 (100). HREIMS calcd for C₂₄H₂₇NO₄:393.1940; found: 393.1930 [M]⁺.

-   8. Typical Procedure for Cell Viability Assay

The breast carcinoma (MCF-7), lung carcinoma (H1299), and prostatecarcinoma (DU145) cells were first plated at a density of 5×10³ cellsper well in 96-well plates for overnight and then treated with differentconcentrations of these compounds. After 48 h of treatment, 100 μL ofMTT solution was added to each well and the cells were incubated for 1 hat 37° C. Then, the MTT solution was completely removed and 50 μL, ofDMSO was added to solubilize the MTT fonnazan crystals. Finally, theabsorbance was measured using a MQX200R microplate reader (BioTek, VT,USA) at a wavelength of 550 nm.

-   9. The Effect of Compound 20 on H1299 Cell Cycle Associated Protein-   9.1 Western Blot Analysis

H1299 cells were first seeded at a density of 3×10⁵ cells per well insix-well plates overnight and then treated with compound 20 at threedifferent concentrations (7, 14, and 21 nM) for 12, 24, and 48 h. Thecells were washed with PBS buffer and lysed in ice-cold RIPA buffer for30 min. The supernatant was collected and centrifuged at 15,000 rpm at4° C. for 30 min. The protein concentration was measured with a Bio-Radassay using a MQX200R microplate reader (BioTek, VT, USA). The celllysates were separated by 10% SDS-PAGE and electrophoreticallytransferred onto polyvinylidene difluoride (PVDF) membranes (Millipore,Bedford, MA). After several washes, the membranes were blocked with 5%skim milk in TBST (tris-buffered saline containing 0.1% Tween-20) atroom temperature for 1 h and incubated with different primary antibodiesagainst cyclin D1, CDK4, cyclin E, CDK2, cyclin B1, and CDK1 (1:2000dilution) at 4° C. for overnight. Then, the membranes were washed withTBST three times and investigated using horseradish peroxidase(HRP)-conjugated secondary antibody (1:4000) at room temperature for 1h. After washing three times in TBST, the bound antibody was visualizedusing ECL Western Blotting Reagent (PerkinElmer, Boston), andchemiluminescence was detected using a Fuji Medical X-ray film (Tokyo,Japan).

-   9.2 Statistical Analysis

All the data were expressed as means±SEM for three replicateexperiments. The statistical comparison between the treatments wascarried out using the GraphPad. Prism 5.0 software. One-way ANOVAfollowed, by Tukey's honestly significant difference (HSD) posthoc testwere applied, with significances of P<0.05 or P<0.01.

-   10. Rotarod Test for Motor Coordination

The protocol of rotarod test was based, on those described in theliterature [Y. Z. Lee, C. W Yang, H. Y. Hsu, Y. Q. Qiu, T. K. Yeh, H. Y.Chang, et al., T. Med. Chem. 2012, 55, 10363-10377] with slightmodifications. Eightweek-old female athymic nude mice were used. All theanimal experiments followed ethical standards, and the protocols havebeen reviewed and approved by the Animal Care and Use Committee of ChinaMedical University (IACUC approval no: 102-235-N). The mice wererandomly divided into two groups (n=3) and treated with compound 20 (10mg/kg) or 7-methoxycryptopleurine 5i (0.08 mg/kg) intraperitoneally. Thecompounds were dissolved in a mixture of 2.5% DIVISO, 2.5% EtOH, 5%Cremophor EL, and 90% normal saline. Each group was administered oncedaily, five days per week for 15 times in total. After 15administrations of the compounds, the mice were placed on the rotarodapparatus for training (day 1) and test (days 2-4) with the rod set inmotion at a constant speed of 5 rpm. The latency time to fall from therotating rod was recorded for a maximum of 180 s.

-   11. Results

Tthe cytotoxic activities of 18 compounds 4a-i and 5a-i were evaluatedagainst three human cancer cell lines, breast carcinoma (MCF-7), lungcarcinoma (H1299), and prostate carcinoma (DU145), using tylophorine(4i) and 7-methoxycryptopleurine (5i) for comparison. The cytotoxicactivities of phenanthroindolizidines 4a-i and phenanthroquinolizidines5a-i are shown in Table 4. First, all the phenanthroquinolizidines 5a-iwere more active than the corresponding phenanthroindolizidines 4a-i.¹⁴Moreover, a 28 to 36-fold increase in the cytotoxicity was observed forcompound 51 relative to compound 4f (entry 6). This indicates that thephenanthroquinolizidines tolerated more substituent changes at the C-6position than phenanthroindolizidines. In the phenanthroindolizidineseries, the IC₅₀ ratio of compounds 4a-h to tylophorine (4i) followedthe order: 4a˜4h˜4c>4f>>4b˜4e>4d>4g; however, in thephenanthroquinolizidine series, the IC₅₀ ratio of compounds 5a-h to7-methoxycryptopleurine (5i) followed the order:5c˜5a˜5h˜5b>>5f˜5d>5e>5g. The data indicate that when the C-1 and C-8substituents were converted from methoxy to hydrogen and the C-3substituent was converted from hydrogen to methoxy, the cytotoxicitydecreased dramatically. Interestingly, C-6 methoxylation is moreimportant than C-2 methoxylation for cytotoxicity in thephenanthroindolizidine series, whereas a reverse trend was observed inthe phenanthroquinolizidine series. Moreover, the C-4 and C-5methoxylation showed only slightly deleterious effects on thecytotoxicity (entries 4 and 5 vs. entry 9). Notably, the absence of amethoxy group at the C-7 position did not significantly affect thecytotoxicity in the two series of alkaloids (entry 7 vs. entry 9). Basedon the SAR results, a more polar phenanthroquinolizidine,7-hydroxycryptopleurine (20), was designed and synthesized to decreasethe CNS toxicity and increase the water solubility7-Flydroxycryptopleurine (20) was obtained from3-benzyloxy-4-methoxybenzaldehyde in 40.7% overall yield by the abovenewly developed method.

TABLE 4 IC₅₀ values of compounds 4a-i and 5a-i against three humancancer cell lines. Com- pound IC₅₀ (nM)^([a]) Entry 4 {5} MCF-7 H1299DU145 1 4a {5a} >2500 {276.4} >2500 {251.9} >2500 {271.9} 2 4b {5b}304.9 {272.4} 235.2 {210.6} 175.6 {184.5} 3 4c {5c} 2481.0 {392.5} >2500{314.4} 2152.0 {278.9} 4 4d {5d} 61.2 {61.9} 54.1 {54.4} 58.8 {35.7} 54e {5e} 223.9 {19.3} 165.3 {27.6} 150.1 {23.8} 6 4f {5f} 1909.0 {68.7}2017.0 {57.3} 1510.0 {41.8} 7 4g {5g} 42.4 {11.3} 32.5 {9.0} 30.3 {4.6}8 4h {5h} >2500 {277.4} >2500 {232.4} >2500 {214.9} 9 4i {5i} 41.1{10.7} 30.9 {7.1} 28.3 {4.5} ^([a])The values in the brackets show theIC₅₀ of compounds 5.

Compound 20 exhibited potent cytotoxicity activity against MCF-7, H1299,and DU145 cancer cell lines, with IC₅₀ values of 6.4, 5.2, and 4.4 nM,respectively. The normal human lung fibroblast cell line, MRC-5, wasmore resistant than other cancer cell lines (IC₅₀ 26.0 nM). The resultsindicate that compound 20 possesses enhanced and selective cytotoxicityfor cancer cells. The antiproliferative activity of compound 20 in H1299cancer cells was partly mediated by a decrease in cyclin D1-cdk4, cyclinE-cdk2, and cyclin B1-cdk1 expression. Moreover, compound 20 was solublein the solvent system—2.5% DMSO, 2.5% EtOH, 5% Cremophor EL, and 90%normal saline—in the range of ˜1.3 mg/mL, whereas the solubility of7-methoxycryptopleurine (5i) was less than 0.08 mg/mL. The neurotoxicityof the compounds was investigated by a rotarod test for motorcoordination for three consecutive days. The compound 20-treated groupexhibited better motor coordination than the compound 5i-treated group,as shown in FIG. 1.

The term “alkyl” refers to a straight or branched hydrocarbon,containing 1-10 carbon atoms. Examples of alkyl groups include, but arenot limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, andt-butyl. The term “alkoxy” refers to a univalent radical alkyl-0-, e.g.CH₃O—.

The term “aryl” refers to a 6-carbon monocyclic, 10-carbon bicyclic,14-carbon tricyclic aromatic ring system wherein each ring may have 1 to4 substituents. Examples of aryl groups include, but are not limited to,phenyl, naphthyl, and anthracenyl.

The term “cyclyl” refers to a saturated and partially unsaturated cyclichydrocarbon group having 3 to 12 carbons, preferably 3 to 8 carbons, andmore preferably 3 to 6 carbons, wherein the cyclyl group may beoptionally substituted. Examples of cyclyl groups include, withoutlimitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

The term “heteroaryl” refers to an aromatic 5-8 membered monocyclic,8-12 membered bicyclic, or 11-14 membered tricyclic ring system having1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9heteroatoms if tricyclic, said heteroatoms selected from O, N, or S(e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S ifmonocyclic, bicyclic, or tricyclic, respectively), wherein each ring mayhave 1 to 4 substituents. Examples of heteroaryl groups include pyridyl,furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl orthienyl, quinolinyl, indolyl, thiazolyl, and the like.

The term “heterocyclyl” refers to a nonaromatic 5-8 membered monocyclic,8-12 membered bicyclic, or 11-14 membered tricyclic ring system having1-3 heteroatoms if monocyclic, 1-6 heteroatoms if bicyclic, or 1-9heteroatoms if tricyclic, said heteroatoms selected from O, N, or S(e.g., carbon atoms and 1-3, 1-6, or 1-9 heteroatoms of N, O, or S ifmonocyclic, bicyclic, or tricyclic, respectively), wherein 0, 1, 2 or 3atoms of each ring may be substituted by a substituent. Examples ofheterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl,morpholinyl, tetrahydrofuranyl, and the like.

Alkyl, aryl, cyclyl, heteroaryl, and heterocyclyl mentioned hereininclude both substituted and unsubstituted moieties. Examples of asubstituent include, but are not limited to, halo, hydroxyl, amino,cyano, nitro, mercapto, alkoxycarbonyl, amido, carboxy, alkanesulfonyl,alkylcarbonyl, carbamido, carbamyl, carboxyl, thioureido, thiocyanato,sulfonamido, alkyl, alkenyl, alkynyl, alkyloxy, aryl, heteroaryl,cyclyl, heterocyclyl, in which alkyl, alkenyl, alkynyl, alkyloxy, aryl,heteroaryl cyclyl, and heterocyclyl are optionally further substituted.with alkyl, aryl, heteroaryl, halogen, hydroxyl, amino, mercapto, cyano,or nitro.

The compounds mentioned above may contain one or more asymmetriccenters. Thus, they occur as racemates and racemic mixtures, singleenantiomers, individual diastereomers, diastereomeric mixtures, or cis-or trans-isomeric forms. All such isomeric forms are contemplated.

1. An improved method for preparing a phenanthroindolizidine andphenanthroquinolizidine alkaloid having a structure represented by thefollowing formula (I):

wherein n is 1, 2, or 3; and each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰, R¹¹, R¹², R¹³ , R¹⁴, and R¹⁵, independently, is H, halogen, alkyl,aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, or amino; andwherein the improvement comprises the method comprising step (5):conducting a reductive decyanization reaction of an atninoacrylonitrilederivative having a structure represented by the following formula (11I)to obtain a diphenyltetrahydropyridine derivative having a structurerepresented by the following formula (II):


2. The method of claim
 1. further comprising a step (6): conducting anaryl-aryl oxidative coupling reaction of the diphenyltetrahydropyridinederivative (II) to obtain the phenanthroindolizidine andphenanthroquinolizidine alkaloid (I).
 3. The method of claim 1 furthercomprising a step (4): conducting an intramolecular aza-Diels-Alderreaction of an iminonitrile derivative having a structure represented bythe following formula (IV) and to obtain the aminoaerylonitrilederivative (III):

wherein n is 1, 2, or 3; and each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and. R¹⁵, independently, is H, halogen, alkyl,aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, or amino.
 4. Themethod of claim 3 further comprising step (3): reacting a vinyl aminederivative having a structure represented by the following formula (V)with an (E)-2,3-diphenylacrylaidehyde derivative having a structurerepresented by the following formula (VI) to obtain the iminonitrilederivative (EV):HR⁹C═C—CR¹⁰R¹¹—(CR¹⁴R¹⁵)_(n)—CR¹²R¹³NH₂   (V)

wherein n is 1, 2, or 3; and each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, independently, is H, halogen, alkyl,aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, or amino.
 5. Themethod of claim 4 further comprising a step (2): conducting adiisobutylaluminum hydride reduction of a diphenyl lacrylonitrilederivative having a structure represented by the following formula (VII)to obtain the (E)-2,3-diphenylacrylaidehyde derivative (VI):

wherein each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸, independently, is H,halogen, alkyl, aryl, cyclyl, heteroaryl, heterocyc,Iyi, OH, alkoxy, oramino.
 6. The method of claim 5 further comprising a step (1):conducting a Knoevenagel condensation of a benzaldehyde derivativehaving a structure represented by the following formula (VIII) and aphenylacetonitrile derivative having a structure represented by thefollowing formula (IX) to obtain the diphenylacryionitrile derivative(VII):

wherein each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸, independently, ishalogen, alkyl, aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, oramino.
 7. A phenanthroindolizidine and phenanthroquinolizidine alkaloidhaving a structure represented by the following formula (I),

wherein n is 1, 2, or 3; and each of R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹,R¹⁰ , R¹¹, R¹², R¹³, R¹⁴, and R¹⁵, independently, is H, halogen, alkyl,aryl, cyclyl, heteroaryl, heterocyclyl, OH, alkoxy, or amino; wherein atleast one of R¹, R², R³, R⁴, R⁵, R⁶, R⁷ and R⁸ is OH; and wherein thealkaloid (I) exists without mixing with another phenanthroindolizidineand phenanthroquinolizidine alkaloid.
 8. The phenanthroindolizidine andphenanthroquinolizidine alkaloid of claim 7, which is dissolved in wateror an aqueous solution.
 9. The method of claim 1, wherein n=2; and R¹,R⁸, R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴ and R¹⁵ are H.
 10. The method of claim9, wherein each of R², R³, R⁴, R⁵, R⁶, and R⁷, independently, is H, OH,or alkoxy.
 11. The method of claim 10, wherein at least one of R², R³,R⁴, R⁵, R⁶, and R⁷ is OH.
 12. The method of claim 11, wherein R², R³,and R⁶ are methoxy; and R⁷ is OH.
 13. The phenanthroindolizidine andphenanthroquinolizidine alkaloid of claim 7, wherein n=2; and R¹, R⁸,R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵ are H.
 14. Thephenanthroindolizidine and phenanthroquinolizidine alkaloid of claim 13,wherein each of R², R³, R⁴, R⁵, R⁶, and R⁷, independently, is H, OH, oralkoxy.
 15. The phenanthroindolizidine and phenanthroquinolizidinealkaloid of claim 14, wherein R², R³, and R⁶ are methoxy; and R⁷ is OH.16. A method for treating a cancer comprising administering to a subjectin need thereof an effective amount of a phenanthroindolizidine andphenanthroquinolizidine alkaloid having a structure represented by thefollowing formula (I):

wherein n=2; R⁹, R¹⁰, R¹¹, R¹², R¹³, R¹⁴, and R¹⁵ are H; R², R³, and R⁶are alkoxy; R¹, R⁴, R⁵, R⁷ and R⁸, independently, are H, OH, or alkoxy;and at least one of R¹, R⁴, R⁵, R⁷ and R⁸ is OH; and wherein the canceris selected from the group consisting of breast cancer, lung cancer, andprostate cancer.
 17. The method of claim 16, wherein R², R³, and R⁶ aremethoxy ; R¹, R⁴, R⁵, and R⁸, independently, are H or methoxy; and R⁷ isOH.
 18. The method of claim 17, wherein the alkaloid has a structurerepresented by following formula: